Aviva Insurance Limited

Solvency and Financial Condition Report Year ended 31 December 2016



Contents

	Summary
Α	Business and Performance
В	System of Governance
С	Risk Profile
D	Valuation for Solvency Purposes
Е	Capital Management
F	Appendices
F.1	Public Disclosure Quantitative Reporting Templates
F.1.1 F.1.2.1 F.1.2.2 F.1.2.3 F.1.2.4 F.1.3.1 F.1.3.2 F.1.4 F.1.5 F.1.6 F.1.7 F.1.8	S.02.01 Balance Sheet S.05.01 Premium claims and expenses (by line of business) [life] S.05.01 Premium claims and expenses (by line of business) [non-life] S.05.02 Premium claims and expenses (by country) [life] S.05.02 Premium claims and expenses (by country) [non-life] S.12.01 Technical Provisions [life] S.17.01 Technical Provisions [non-life] S.19.01 Insurance claims [non-life] S.22.01 Impact of transitional measures S.23.01 Own Funds S.25.02 Solvency Capital Requirement S.28.01 Minimum Capital Requirement
F.2 F.3 F.4	Glossary of Abbreviations and Definitions Directors' Statement Auditors' Report

Aviva Insurance Limited

Solvency and Financial Condition Report

2016

Summary

The purpose of the Solvency and Financial Condition Report is to provide information about the capital position at 31 December 2016 of the Company based on the Solvency II (SII) requirements.

The report sets out different aspects of the Company's business and performance, system of governance, risk profile, valuation methods used for solvency purposes and its capital management practices.

Business and Performance

The Company is a limited company registered in Scotland and member of the Aviva plc group of companies. The Company transacts general and health insurance business in the United Kingdom and Ireland. The major classes of business underwritten are personal lines (motor, home, creditor and other), and health and commercial lines (property, liability, motor and other).

The Company made a loss before tax of £340m in the year ended 31 December 2016. This comprises an underwriting profit of £139m, net investment income of £314m and other costs of £793m. Other costs of £793m include the impact of a reduction in the Ogden discount rate (see below).

Underwriting profit benefited from premium growth, benign weather and improved expenses during the year. On 1 January 2016, the Company increased its 5% retrospective (both new and existing business) quota share reinsurance arrangement with fellow subsidiary Aviva International Insurance Ltd (AIIL) to 50%. The Company's underwriting profit of £139m is net of new business ceded to AIIL in the year of £110m.

Net investment income includes £168m dividends received from subsidiaries and £80m interest earned on loans to Group undertakings. The Company also ceded £134m of investment income to AIIL under the quota share reinsurance arrangement.

The Company incurred other costs of £793m during the year which include the following items:

- On 1 January 2016, the execution of the increase in the quota share reinsurance arrangement with AIIL from 5% to 50% resulted in a net impact of £309m.
- On 27 February 2017, the Lord Chancellor announced a reduction in the discount rate used in the Ogden tables, which are used in the settlement of lump sum payments in bodily injury claims, from 2.5% set in 2001 to minus 0.75%. The Company's IFRS claims reserves have been strengthened by £238m, net of all reinsurance, to allow for the impact of the reduction in the current discount rate.
- The impact of changes in economic assumptions used to value IFRS claims provisions resulted in a net cost of £115m.
- Costs recharged to the Company during the year in respect of closed defined benefit pensions schemes amounted to £68m.

Section A of this report sets out further details about the Company's key operations and financial performance over the reporting period.

System of Governance

The Board's responsibility includes ensuring that an appropriate system of governance is in place throughout the Company. To discharge this responsibility, the Board has established frameworks for risk management and internal control using a 'three lines of defence' model. However, the Board sets the Company's risk appetite itself. A strong system of governance throughout the Company aids effective decision-making and supports the achievement of the Company's objectives for the benefit of customers, shareholders and regulators. Key features of the Company's System of Governance are as follows:

- The roles and responsibilities of the Board and its committees are well defined;
- The Company has implemented four key control functions Risk, Actuarial, Compliance and Internal Audit;
- The Company has in place a remuneration policy, skills requirements and procedures for assessing the fitness and propriety of senior management and key function holders;
- The Company's risk strategy, appetite and framework, its approach to its Own Risk and Solvency
 Assessment (ORSA), and its governance over its Partial Internal Model (PIM) are set out in its Risk
 Management Framework policy and its risk policies and business standards;
- The Company's outsourcing strategy is supported by the Procurement and Outsourcing Business Standard.

Section B of this report provides further details of the Company's System of Governance.

Risk Profile

The Company's business is about protecting its customers from risk. As an insurer, the Company accepts the risks inherent to its core business line of non-life insurance. Risks are diversified through the Company's scale, geographical distribution, the variety of the products and services offered and the channels through which they are sold.

The Company receives premiums which are invested in order to maximise risk-adjusted returns, so that the Company can fulfil its promises to customers while providing a return to its shareholders. In doing so, the Company has a preference for retaining those risks which it believes it is capable of managing to generate a return.

The types of risk to which the Company is exposed have not changed significantly over the year and remain credit, market, underwriting, liquidity and operational risks.

For those risk types managed through the holding of capital, the Company measures and monitors risk profile on the basis of the SII Capital Requirement (SCR). Some categories of risk are not measured and managed solely by holding capital, principally liquidity risk, which is measured through both absolute level targets and bespoke liquidity coverage ratios.

Section C of this report further describes the risks to which the Company is exposed and how it measures, monitors, manages and mitigates these risks, including any changes in the year to risk exposures and specific risk mitigation actions taken.

Valuation for Solvency Purposes

Assets, Technical Provisions and other liabilities are valued in the Company's SII Balance Sheet according to the SII regulations. The principle that underlies the valuation methodology for SII purposes is the amount for which they could be exchanged, transferred or settled by knowledgeable and willing third parties in an arm's length transaction. The value of technical provisions under SII is equal to the sum of a Best Estimate Liability and a risk margin.

At 31 December 2016, the Company's excess of assets over liabilities was £2.3bn on a SII basis which is £1.9bn lower than the value under IFRS. The difference is primarily driven by the different bases used to value the Company's participations in its subsidiaries.

Section D of this report provides further description of the bases, methods and main assumptions used in the valuation of assets, technical provisions and other liabilities for each material asset/liability class. In addition, it also provides an explanation of the material differences between the IFRS and SII bases of valuation.

Capital Management

The Company manages Own Funds in conjunction with solvency capital requirements. In the calculation of the SCR, the Company has chosen to implement a PIM, defined as using a combination of Internal Model (IM) and Standard Formula (SF) approaches to calculate solvency capital requirements for different components of its business.

In managing capital, the Company seeks, on a consistent basis, to:

- Match the profile of its assets and liabilities, taking into account the risks inherent in the business;
- Maintain sufficient, but not excessive financial strength in accordance with risk appetite, to support new
 business growth and satisfy the requirements of the Company's regulators and other stakeholders giving
 the Company's customers assurance of its financial strength;
- Retain financial flexibility by maintaining strong liquidity;
- Allocate capital rigorously to support value adding growth and repatriate excess capital where appropriate.

At 31 December 2016, the total eligible Own Funds to meet the SCR was £2.6bn, 85% of which was represented by unrestricted tier 1 capital. The Company's SCR, at 31 December 2016, was £1.3bn. The overall surplus position was £1.3bn which translates to a regulatory cover ratio of 209%.

Section E of this report further describes the objectives, policies and procedures employed by the Company for managing its Own Funds. The section also covers information on structure and quality of Own Funds and calculation of SCR, including information about the Company's PIM.

Aviva Insurance Limited Solvency and Financial Condition Report 2016

A. Business and Performance

In this Chapter

- A.1 Business
- A.2 Underwriting Performance
- A.3 Investment Performance
- A.4 Performance of Other Activities
- A.5 Any Other Information

A. Business and Performance

The 'Business and Performance' section of the report sets out the Company's business structure, key operations, and financial performance over the reporting period.

A.1 Business

The Company is a limited company registered in Scotland and is a member of the Aviva plc group of companies.

Qualifying holdings

The Company's shares and the associated voting rights are wholly owned by Aviva Group Holdings Limited (AGH), being a qualifying holding in the Company.

Supervisor

The Company is authorised by the Prudential Regulatory Authority (PRA). The Company and the Group are regulated by the PRA and the Financial Conduct Authority (FCA) in the UK. The PRA is part of the Bank of England. Contact details for the PRA are as follows:

Address 20 Moorgate, London, EC2R 6DA

Telephone number +44 (0) 20 7601 4444

External auditor

The Company's external auditor is PricewaterhouseCoopers LLP. Contact details are as follows:

Address 7 More London Riverside, London, SE1 2RT


Telephone number +44 (0) 20 7583 5000

Financial statements

The Company's financial statements are available from the Company Secretary, Aviva Company Secretarial Services Limited, St Helen's, Undershaft, London, EC3P 3DQ.

A.1.1 Organisation

The following chart shows, in simplified form, the Company's position within the structure of the Group as at 31 December 2016:



- * Incorporated in the United Kingdom
- ** Incorporated in Canada
- *** Incorporated in Ireland

AGH is the immediate parent entity of the Company and Aviva plc is the ultimate controlling parent entity, both are registered in England and Wales. The chart above also presents the Company's material subsidiaries as at 31 December 2016. All of the Company's material subsidiaries are wholly owned by the Company.

A.1.2 Business operations and events occurring in the year

Business operations

The Company primarily transacts general and health insurance business in the UK and Ireland.

The major classes of business underwritten are personal lines (motor, home, creditor and other), and health and commercial lines (property, liability, motor and other). Whilst the Company only conducts non-life insurance activities, the Company has material life insurance obligations in the UK in relation to annuities stemming from non-life insurance contracts also known as Periodic Payment Orders (PPOs).

Significant business and other events

The SII regime came into effect from 1 January 2016. The Company, as part of the wider approval received by Aviva plc in December 2015, has been authorised to use a PIM approach to calculate its SCR.

During 2014, the Group established AIIL, a fellow Aviva Group subsidiary, as its UK onshore risk retention vehicle which improved fungibility of capital within the Group and also brought Aviva more in line with its large pan-European peers. On 1 January 2016, the Company increased its 5% retrospective (both new and existing business) quota share reinsurance arrangement with AIIL to 50%. £5,218m of net earned premium in 2016 was ceded to AIIL under this arrangement, of which £2,919m was ceded on execution of the contract relating to 2015 and prior years.

On 27 February 2017, the Lord Chancellor announced a reduction in the discount rate used in the Ogden tables, which are used in the settlement of lump sum payments in bodily injury claims, from 2.5% set in 2001 to minus 0.75%. The Company's IFRS claims provisions, net of all reinsurance, have been strengthened by £238m to allow for the impact of the reduction in the current Ogden discount rate. The impact on the Company's SII capital surplus was to reduce it by circa. £0.1bn. The Lord Chancellor has also announced that the framework for setting the discount rate is under review. A public consultation was launched on 27 March 2017.

As part of the restructuring carried out in 2013, the Company entered into a loan to AGH. The Company's loan to AGH has reduced from £2,413m at 31 December 2015 to £1,513m at 31 December 2016. This was achieved through the offset of dividends due to AGH of £900m.

In June 2016, the Company issued a subordinated loan to AGH of £290m and used the proceeds to provide a subordinated unsecured loan to Aviva Canada Inc. (ACI) of £290m on similar terms.

A.2 Underwriting Performance

A.2.1 Measurement of underwriting performance

The Company uses underwriting result to measure its underwriting performance. Underwriting result is a non-GAAP financial performance measure, calculated on an IFRS basis. It excludes certain items to enhance comparability and understanding of underwriting performance by highlighting net underwriting income attributable to on-going underwriting operations. Examples of items excluded from underwriting result are investment return, economic assumption changes and amortisation of intangible assets. The items excluded from underwriting result, which comprise the Company's investment performance and its performance of other activities, are detailed in sections A.3 and A.4 respectively.

A.2.2 Underwriting performance during the year

The table below presents the underwriting profit for the Company for the year ended 31 December 2016, as well as the reconciliation of underwriting profit to loss before tax. The loss before tax is as shown in the Company's financial statements.

Year ended 31 December 2016	£m	£m
Gross written premiums		5,100
Premiums ceded to reinsurers		(5,720)
Premiums written net of reinsurance		(620)
Net change in provision for unearned premium		884
Net earned premiums		264
Fee and commission income, net of reinsurance		24
Net investment income		314
Income		602
Claims paid net of recoveries from reinsurers		(1,508)
Change in insurance liabilities, net of reinsurance		1,636
Fee and commission expense, net of reinsurance		(834)
Other expenses, net of reinsurance		(235)
Finance cost		(1)
Loss for the year before tax		(340)
Less: Net investment income (above, see A.3)		(314)
Add back:		
Impact on execution of the reinsurance transaction to increase the quota share from 5% to		
50%	309	
Strengthening of claims provisions, net of all reinsurance, to allow for the impact of the		
reduction in the Ogden discount rate	238	
Changes in economic assumptions for claims provisions	115	
Pension costs recharged to the Company for closed defined benefit schemes	68	
Other	63	
Performance of other activities (see A.4)		793
Underwriting profit		139

The Company earned underwriting profit of £126m principally in the UK and £13m in Ireland.

The Company's underwriting profit of £139m is net of new business ceded to AllL in the year of £110m. The underwriting profit of £139m excludes the strengthening of claims provisions, net of all reinsurance, by £238m to allow for the impact of the reduction in the current Ogden discount rate referred to in A.1.2 above.

In the UK, gross written premiums were up 6%. Premiums for Fire and Other Damage to Property were up, including the benefit from the new distribution partnership with Homeserve. Motor Vehicle Liability and Other Motor premiums were up with volumes stable as retention remained broadly flat. New business rating was in line with the market. Commercial premiums, (within Motor Vehicle Liability, Other Motor, Fire and Other Damage to Property and General Liability) were stable, reflecting rating action in the Commercial Motor book, and selective growth and exits across the book in continued soft market conditions.

Ireland saw a 35% growth, driven by foreign exchange movements and increases in motor products, reflecting continued rating and account improvement actions.

Gross earned premium increased in Motor Vehicle Liability and Other Motor driven by the increase in personal motor sales in UK and Ireland. It increased in Fire and Other Damage to Property driven by HomeServe.

Underlying claims experience in Fire and Other Damage to Property benefited from benign weather, whereas commission was driven higher from a change in mix of business, particularly from the new HomeServe partnership.

Expenses across all lines of business improved during the year, reflecting the continued focus on cost control and a reduction in integration and restructuring costs, partly offset by the cost of the new 2016 Flood Re Levy.

A.2.3 Solvency II lines of business

Quantification of premiums, claims and expenses, analysed by SII line of business, is provided in Quantitative Reporting Templates (QRT) S.05.01, (Appendix F.1.2.1 and F.1.2.2). These QRT have been prepared in accordance with the definitions and formats prescribed under SII. These QRT include the items (except net investment income) excluded from underwriting result in the reconciliation presented in section A.2.2. These items are described in section A.4.

A summary of the information provided in the premium, claims and expenses QRT S.05.01 is provided in the table below.

For the year ended 31 December 2016 £m	Medical expense insurance	Motor vehicle liability insurance	Other motor insurance	Fire and other damage to property insurance	General liability insurance	Annuities stemming from non- life contracts	Other	Total
Gross written premium	564	1,489	378	1,982	400	-	287	5,100
Net earned premium	263	(273)	(62)	648	(353)	-	41	264
Gross claims incurred	(417)	(1,485)	(329)	(766)	(424)	(213)	(145)	(3,779)
Net claims incurred	(193)	124	61	(122)	339	(48)	(11)	150
Direct expenses incurred	(59)	(212)	(54)	(518)	(74)	-	(55)	(972)

The material SII lines of business underwritten by the Company, in order of the value of gross written premium in the year, as presented in QRT S.05.01 (Appendix F.1.2.1 and F.1.2.2), are:

- Fire and other damage to property insurance 39%
- Motor vehicle liability insurance 29%
- Medical expense insurance 11%
- General liability insurance 8%
- Other motor insurance 7%

The net earned premium ceded to AILL during the year includes £2,919m ceded on execution of the contract and relating to 2015 and prior years. The effect of this premium ceded is to reduce net earned premium, particularly for Motor Vehicle Liability, Other Motor and General Liability because associated premium income for these lines of business was substantially earned on premium written in 2015 and prior years due to a longer tail. As a result, net earned premium for these lines of business is negative, as shown in the table above.

Conversely, the net claims reserves ceded to AllL on execution of the contract and relating to 2015 and prior years has particularly benefited these same lines of business. As a result, net claims incurred for these lines of business are positive.

Gross and net claims incurred for Motor Vehicle Liability and Other Motor shown in the table above are adversely impacted by the effects of the change in the Ogden discount rate, see section A.4.1 for further information.

A.3 Investment Performance

A.3.1 Measurement of investment performance

Net investment income, as shown in the Company's financial statements, is used as the measure to report the Company's investment performance.

Net investment income analysed by asset class

The Company's net investment income for the year was £314m. The table below provides an analysis of net investment income by asset class.

Net investment income For the year ended 31 December 2016 £m	Investments in subsidiaries	Debt securities	Other financial investments	Loans with Group companies	Interest payable under quota share reinsurance with AIIL	Investment Property	Total
Dividend income	168	-	4	-	-	-	172
Interest income/(expense)	-	100	8	80	(134)	-	54
Unrealised gains/(losses)	-	208	(42)	-	-	(3)	163
Realised gains/(losses)	-	6	(84)	-	-	-	(78)
Rental income less expense	-	-	-	-	-	9	9
Other (incl. investment expenses)							(6)
Total	168	314	(114)	80	(134)	6	314

The Company's sources of material investment income during the year are:

- Dividend income from investments in subsidiaries;
- Interest receivable on financial investments;
- Net unrealised gains on financial investments, resulting from underlying market performance.

Losses have arisen on other financial assets, mainly on derivatives resulting from movements in foreign exchange rates and inflation. Derivatives are used for risk reduction and efficient portfolio management purposes.

Under the terms of the reinsurance arrangement with AIIL, the Company withheld the majority of the payment due to AIIL. Interest of £134m accrued on the amount withheld.

Net investment income of £314m is stated after deduction of £6m of investment expenses.

A.3.2 Gains and losses recognised directly in equity

Gains and losses recognised directly in equity include fair value gains on investments in subsidiaries £403m, impairment losses on investments in subsidiaries previously revalued through other comprehensive income, now taken to the income statement, £20m, and foreign exchange rate gains, £17m. These are detailed in the Statement of Comprehensive Income on page 24 of the Company's financial statements.

A.4 Performance of other activities

A.4.1 Other income and expense

As described in section A.2.1, performance of other activities comprises those items of other income and expense, other than net investment return, excluded from underwriting result. The table in section A.2.2 summarises the loss of £793m that the Company sustained from its performance of other activities during the year. The material components are as follows:

Increase in quota share reinsurance arrangement with AIIL from 5% to 50%: £309m

The impact on execution of the reinsurance transaction to increase the quota share from 5% to 50% is detailed in the table below. This related to business from 2015 and prior years.

Increase in quota share arrangement with AIIL from 5% to 50%, Year ended 31 December 2016	£m
Premiums ceded to reinsurers, relating to 2015 and prior years	(2,919)
Change in reinsurer's share of net unearned premium reserve	933
Change in reinsurer's share of insurance liabilities	1,869
Change in deferred acquisition costs	(192)
Loss before tax	(309)

Reduction in Ogden discount rate: £238m

On 27 February 2017, the Lord Chancellor announced a reduction in the discount rate used in the Ogden tables, which are used in the settlement of lump sum payments in bodily injury claims, from 2.5% set in 2001 to minus 0.75%. The Lord Chancellor has also announced that the framework for setting the discount rate is under review. A public consultation was launched on 27 March 2017.

Economic assumption changes for claims provisions: £115m

A loss before tax of £115m arose in 2016 in relation to changes in the economic assumptions used to value claims provisions, reflecting the impact of a decrease in the real interest rates (i.e. net of inflation) used to discount claim reserves for PPO and latent claims.

Contributions to closed defined benefit pension schemes: £68m

The Company has no employees. However, it is one of a number of companies in the Group being charged for the costs of staff participating in defined benefit pension schemes in the UK and its contributions are affected by the financial position of these schemes. The defined benefit sections for the schemes are now closed to both new members and future accrual. In the absence of any contractual arrangements to allocate the net defined benefit cost for these schemes, measured in accordance with IAS 19, to individual businesses it is the policy of the Group to allocate this cost fully to the main employing companies. The Company therefore recognises a pension expense equal to its contributions payable in the year. Full disclosure of the Group's pension schemes is given in the Annual Report and Accounts of the Group. The Company's contributions to closed defined benefit pension schemes during the year were £68m.

A.4.2 Leasing arrangements

The Company's leasing arrangements are described in sections D. 1.6 and D.3.2.

A.5 Any other information

There is no other material information to report regarding the Company's business and performance.

Aviva Insurance Limited

Solvency and Financial Condition Report

2016

B. System of Governance

In this Chapter

- B.1 General Information on the System of Governance
- B.2 Fit and Proper Policy
- B.3 Risk Management System including the Own Risk and Solvency Assessment
- B.4 Internal Control System
- B.5 Internal Audit Function
- B.6 Actuarial Function
- B.7 Outsourcing
- B.8 Any Other Information

B. System of Governance

This section of the report sets out information regarding the 'System of Governance' in place within the Company.

Details of the structure of the undertaking's 'administrative, management or supervisory body' (defined as including the Board, and Board Committees) are provided. The roles, responsibilities and governance of key functions (defined as the Risk, Compliance, Internal Audit and Actuarial functions) are also provided. Other components of the system of governance are also outlined, including the risk management system and internal control system implemented across the business.

B.1 General Information on the System of Governance

B.1.1 Board structure

The Company's Board is responsible for promoting the long-term success of the Company and for setting its strategy. It sets the Company's risk appetite and satisfies itself that financial controls and risk management systems are robust. A strong system of governance throughout the Company aids effective decision-making and supports the achievement of the Company's objectives for the benefit of policyholders and the shareholder.

The Company's Board has established various committees and delegated responsibilities to assist in its oversight of risk management and the approach to internal controls. The duties of the Company's Board and of each of its committees are set out in their respective terms of reference. The terms of reference list both those items that are specifically reserved for decision by the Board and those matters that must be reported to the Board.

The diagram below shows the segregation of responsibilities between the various committees, in addition to a description of the main roles of each.

The Board

Audit Committee

Assist the Board in discharging its responsibilities for monitoring the integrity of the Company's financial statements.

Review the adequacy and effectiveness of the Company's systems of internal control and monitor the effectiveness, performance and objectivity of the internal and external auditors.

Risk Committee

Assist the Board in its oversight of risk within the Company, with particular focus on risk appetite, risk profile and the effectiveness of the Risk Management Framework.

Review the strength of the capital base and the liquidity position and the level of operational risk.

Review the methodology used in determining the Company's capital requirements.

Monitor regulatory requirements in relation to prudential matters.

Ensure that due diligence appraisals are carried out on strategic or material transactions.

Conduct Committee

Assist the Board in its oversight of the Company's conduct strategy, and monitor its effectiveness, and in setting the Company's conduct and financial crime risk appetites and overseeing the Company's profile against them.

Review whether the Company has satisfactory controls in place to ensure that its customers are treated in accordance with business standards and regulatory requirements.

Review any conduct mitigation plans arising from regulatory reviews and the Company's response to such plans.

Manage good and influential relationships with the regulators.

The Company's Board comprises the Chairman (an Independent Non-executive Director (NED)), the Chief Executive Officer (CEO), the CEO of the Group's UK General Insurance business, and five further NEDs (four independent and one appointed by the Group). The three committees comprise independent NEDs only.

The 'three lines of defence model', and roles and responsibilities of key functions

Roles and responsibilities for risk management in the Company are based around the three lines of defence model.

The first line

Management are responsible for the application of the Risk Management Framework, for implementing and monitoring the operation of the system of internal control and for providing assurance to the Audit, Conduct and Risk Committees and the Board.

The second line

- The Risk Function is accountable for the quantitative and qualitative oversight and challenge of the identification, measurement, management, monitoring and reporting of principal risks and for developing the Risk Management Framework;
- The Actuarial Function is accountable for actuarial methodology, reporting to the relevant governing body on the adequacy of reserves and capital requirements, as well as underwriting and reinsurance arrangements; and
- The Compliance Function supports and advises the business on the identification, measurement and management of its regulatory, financial crime and conduct risks and is accountable for monitoring and reporting on the Company's compliance risk profile.

The third line

The Internal Audit Function provides independent and objective assessment on the robustness of the Risk Management Framework and the appropriateness and effectiveness of internal control to the Audit, Conduct and Risk Committees, and to the Board.

Sections B.3.2, B.4.2, B.5 and B.6 detail the roles, responsibilities, authority, resources, independence and reporting lines of the Risk, Compliance, Internal Audit and Actuarial Functions respectively, and how their independence is ensured.

B.1.2 Material changes in the system of governance

There have been no material changes in the system of governance during the year.

B.1.3 Adequacy of the Company's system of governance

An assessment of the effectiveness of the Company's governance, internal control and risk management systems was conducted half-yearly in 2016, and led to the CEO certifying that:

- There are sound risk management and internal control systems that are effective and fit for purpose in place across the business:
- Material existing or emerging risks within the business have been identified and assessed; and
- The business operates in a manner which conforms to the minimum requirements outlined in the Company's risk policies and business standards.

The Chief Risk Officer (CRO) provided his own certificate which states that:

- The Risk Function has reviewed and challenged the process supporting the CEO's certification and is satisfied that it can provide reasonable assurance of the material accuracy and completeness of the CEO's assessment; and
- No material gaps exist in the Risk Management Framework.

Any material risks not previously identified, control weaknesses or non-compliance with the Company's risk policies and business standards or local delegations of authority are highlighted as part of this process. The results of the certification process and details of key failings or weaknesses are reported to the Audit Committee and the Board to enable them to carry out an effectiveness assessment. The Audit Committee, working closely with the Risk Committee, on behalf of the Board, last carried out a full review of the effectiveness of the Company's systems of internal control and risk management in February 2017.

B.1.4 Remuneration policy and practices

The Company's remuneration policy is designed to incentivise and reward employees for achieving business goals in a manner that is consistent with the Company's approach to sound and effective risk management. There are four key principles to the remuneration policy which are outlined below:

- Align to the Company's purpose and strategy;
- Incentivise achievement of the Company's annual business plan and longer term sustainable growth of the business;
- Recognise leaders who achieve the required business results through living the Company's values and behaviours; and
- Ensure risk based decision making and good governance.

Executive directors

The remuneration policy provides market competitive remuneration. Remuneration of executive directors includes a basic salary, variable components, pension contributions and benefits including relocation and mobility. This incentivises executive directors to achieve both the annual business plan and the longer-term strategic objectives of the Company through significant levels of deferral. As well as rewarding the achievement of objectives, variable remuneration can be zero if performance thresholds are not met.

The variable components include an annual bonus and Long Term Incentive Plan. The annual bonus is based on performance in the year. Targets are set annually and pay-out levels are determined based on performance against those targets. A significant proportion of any bonus awarded is deferred into shares which vest after three years. Current performance conditions for the vesting of LTIP are based on two measures. The first measures return on equity and is set as a percentage. The second compares total shareholder return to other similar companies. Half of the Long Term Incentive Plan vests if return on equity exceeds 30% over the three-year performance period (with none of this vesting if performance is less than 24.5%). The other half vests if the total shareholder return is in the upper quintile when compared to the other companies over the three year period (with none of this vesting if performance is below median).

NEDs

NEDs receive a basic annual fee in respect of their Board duties. Further fees are paid for membership and, where appropriate, chairmanship of Board committees. Fees are reviewed annually taking into account market data and trends and the scope of specific Board duties.

The NEDs do not participate in any incentive or performance plans or pension arrangements and do not receive an expense allowance. However, they are reimbursed for reasonable expenses, and any tax arising on those expenses is settled directly by the Company. On the limited occasions when it is appropriate for a NED's spouse or partner to attend a business event, the Company will meet these costs and any tax liabilities that may arise.

Employees

Remuneration arrangements for employees that are not executive directors take account of the seniority and nature of the role, and individual performance. The aim is to provide employees with remuneration packages that are clear and simple to understand, transparent, consistent and fair. Remuneration includes a basic salary, variable components and pension contributions.

The variable components are discretionary and fully flexible as opposed to a contractual entitlement, and there is a possibility of zero awards being made should the performance of the Company or individuals require this. Individual awards are based on a calibrated assessment of performance of individuals relative to peers.

The remuneration of employees in Risk, Compliance, Internal Audit and the Actuarial Function is determined independently of the financial results of the business areas they oversee. This reinforces the independence of these Functions.

Performance criteria for share awards

Shares can be awarded to both executive directors and employees. These vest after three years, in some cases dependent on performance conditions over a three year period, as outlined above.

Pension and early retirement schemes

The Company did not operate any enhanced pension arrangements or early retirement schemes for members of the Board or key function holders.

B.1.5 Material transactions with the shareholder, persons with significant influence on the Company and members of the Board

Material transactions with the shareholder include:

- Loan receivable: As part of the restructuring in 2013, the Company entered into a loan of £5.8bn with AGH. The loan is secured on the UK Life business and a number of the Group's non-UK operations, and has a final maturity date of December 2042. Interest accrues at 308 basis points above 12 month LIBOR until 31 December 2017, after which the interest rate will be as agreed between both parties. The loan agreement requires annual loan repayments of a minimum of £200m to be made until December 2022, subject to AGH's rights of deferral for up to three years under certain conditions. During the year, the loan balance has been reduced by £900m to £1,513m at 31 December 2016. The reduction was settled via set-off of dividends declared to AGH. Interest of £64m was earned on this loan in 2016.
- Loan payable: In June 2016, the Company entered into a subordinated unsecured loan from AGH of CAD 480m. The loan, with a carrying balance of £290m, accrues interest at 474 basis points above the Canadian Dealer Offered Rate and matures in 2046.
- Dividends: Interim ordinary dividends totalling £1,264m on the Company's ordinary shares were declared and settled during 2016. A total of £900m of interim dividends were settled by way of set-off against the loan to AGH; the remainder was settled in cash.

The total compensation to those employees classified as key management, being those having responsibility and authority for planning, directing and controlling the activities of the Company, including the directors, was £9m.

B.2 Fit and Proper Policy

B.2.1 Requirements for the persons who run the Company or who are other key function holders

The Company's requirements for members of the Board and Board committees are set out in a skills matrix. The skills matrix is integral to the Company's succession plans and supporting its commitment to diversity. Additionally, it provides an essential tool to review and reflect on the skills that individual directors currently possess and identifies training and development needs.

The skills matrix considers each of the following areas:

- Insurance and financial markets;
- Business strategy and business models;
- System of governance;
- Financial and actuarial analysis; and
- Regulatory framework and requirements.

The Company's requirements in respect of skills, knowledge and expertise for key function holders are set following engagement with both internal and external subject matter experts in each specialism. These requirements and qualifications are captured within individual role descriptions for each key function role.

B.2.2 Process assessing fitness and propriety

The Company has implemented processes to ensure that individuals employed within it, or acting on its behalf, are both fit and proper in line with the PRA Fit and Proper requirements for individuals subject to the Senior Insurance Managers Regime and the FCA requirements for Approved Persons. This means that as part of recruitment and employee screening an individual's career history will be assessed and validated to establish whether an individual's skills and knowledge are appropriately matched to the role. It also means that checks are in place to ensure that an individual is honest, of good reputation, has integrity and is financially sound.

The governance over the fitness and propriety of individuals includes recruitment, performance management and training. However, to ensure that the Company protects itself against employing individuals who potentially could threaten its customers, properties, facilities or reputation, the majority of its fitness and propriety processes take place at recruitment and more specifically at pre-employment screening. A minimum set of basic screening requirements has been agreed and implemented. Additional enhanced screening requirements are applied for individuals who will run the Company or become key function holders.

Compliance with the initial and ongoing fitness and propriety minimum requirements is reported half-yearly by the CEO to the Risk Committee.

B.3 Risk Management System including the Own Risk and Solvency Assessment B.3.1 Risk Management Framework

The Risk Management Framework forms an integral part of management and Board processes and the decision-making framework across the Company. The key elements are:

- Risk appetite;
- Risk governance, including risk policies and business standards, risk oversight committees and roles and responsibilities;
 and
- The processes used to identify, measure, manage, monitor and report risks (IMMMR), including the use of risk models and stress and scenario testing (SST).

For the purposes of risk identification and measurement risks are usually grouped by risk type: credit, market, liquidity, general insurance and operational risk. Risks falling within these types may affect a number of metrics, including those relating to balance sheet strength, liquidity and profit. They may also affect the performance of products delivered to customers and service provided to customers and distributors, which can be categorised as risks to brand and reputation or as conduct risk.

To promote a consistent and rigorous approach to risk management the Company has adopted a number of risk policies and business standards which set out the risk strategy, appetite, framework and minimum requirements for its operations. Compliance with these policies and standards was confirmed half-yearly in 2016.

A regular top-down key risk identification and assessment process is carried out by the Risk Function. This includes the consideration of emerging risks and is supported by deeper thematic reviews. The risk assessment processes are used to generate risk reports which are shared with the relevant risk committees.

Risk models are an important tool in the measurement of risks and are used to support the monitoring and reporting of the risk profile and in the consideration of the risk management actions available. A range of stress (where one risk factor, such as equity returns, is assumed to vary) and scenario (where combinations of risk factors are assumed to vary) tests are undertaken to evaluate their impact on the business and the management actions available to respond to the conditions envisaged.

The Risk Function is accountable for quantitative and qualitative oversight and challenge of the IMMMR process and for developing the Risk Management Framework. Internal Audit provides an independent assessment of the risk framework and internal control processes.

Board oversight of risk and risk management is maintained on a regular basis through the Risk Committee. The Board has overall responsibility for determining risk appetite, which is an expression of the risk the business is willing to take. Risk appetites are set relative to capital and liquidity.

Economic capital risk targets are also set for each risk type, calculated on the basis of the SII balance sheet. The Company's position against risk appetite is monitored and reported to the Board on a regular basis. Long-term sustainability depends upon the protection of franchise value and good customer relationships. As such, the Company has a risk preference that it will not accept risks that materially impair the reputation of the Company and requires that customers are always treated with integrity. The oversight of risk and risk management is supported by the Asset and Liability Committee (ALCO), which focuses on business and financial risks, and the Operational Risk Committee, which focuses on operational and reputational risks.

B.3.2 Risk Function

The Risk Function is responsible for the design and implementation of the Risk Management Framework, and the design, implementation and independent validation of the Internal Model (IM). The Risk Function reports to the Company's Board on material risks, together with any other specific areas of risk requested by the Board, and assists the Board and management in the effective operation of the Risk Management Framework including, amongst other things, the provision of specialist analysis and quality reviews, an aggregated view of the risk profile, and an assessment of the key risks associated with the business's strategy, major projects, strategic investments and other key decisions.

The Risk Function has authority to review all areas of the Company and has full, free and unrestricted access to all activities, records, property and personnel necessary to complete its work. The CRO has direct management accountability for the Risk Function. Appointment and removal of the CRO are matters reserved for the Board, on the recommendation of the Risk Committee, which supports the independence of the Risk Function.

Sections B.3.1 and this section explain how risk management is integrated into the organisational structure and the decision-making process. To further support the role of risk management in decision-making processes, the role of the 'first line' is critical as part of the three lines of defence model. The CEO is responsible for the implementation of the Company's strategies, plans and policies, the monitoring of operational and financial performance, the assessment and control of financial, business and operational risks and the maintenance and ongoing development of a robust control framework and environment in their areas of responsibility. Chaired by the Chief Financial Officer (CFO), ALCO assists the CFO with the discharge of his responsibilities in relation to management of the Company's balance sheet within risk appetite and provides financial and insurance risk management oversight. The Operational Risk Committee is chaired by the CFO. It supports the first line owners of key operations and franchise risks in the discharge of their responsibilities in relation to operational risk management.

B.3.3 ORSA

The Company considers that its ORSA comprises all the processes and tools that underpin the consideration of risk and capital implications in key decisions, including business planning. It provides a continuous and forward-looking assessment of the short-term and long-term risks that the Company faces, or may face, and ensures that its capital requirements are met at all times.

The ORSA therefore comprises a number of elements of the Risk Management Framework, which are embedded in the business through the requirements of the business standards around capital allocation, strategy, business planning and stress testing. These elements create an overview of the impact of risk on the business, which are taken into account by management in day-to-day decision-making. In particular, using economic capital in decision-making ensures risk and capital management are connected. The outcomes of the ORSA processes provide the Company's Board and management with insights on the key risks and current and future capital requirements.

The CEO and his direct reports are responsible for the majority of the underlying ORSA processes set out above. The Risk Function is responsible for the design of the Risk Management Framework, including the ORSA, the annual ORSA effectiveness review and annual ORSA reporting.

Review and approval

The outputs from the ORSA processes are reported to and reviewed by the Board and the Risk Committee regularly during the year. The Risk Committee sets the approach to the ORSA and on behalf of the Board oversees the ORSA processes including the identification of risk, the methodology and assumptions used in the IM, and the results of the IM validation exercise. The results of the Company's ORSA processes are considered by the Board when reviewing the Company's strategy and approving annually the three year business and capital plan.

The annual ORSA Report brings together and summarises a high level description of the key components of ORSA, together with key developments and outcomes during the year. This is submitted to the Board, and subject to their approval shared with the

The Board confirmed the use of the regulatory capital requirement plus a risk appetite buffer as the Company's own measure of capital for the purposes of the ORSA.

Economic capital (as a risk based capital measure) is embedded in the Company's Risk Management Framework and is used as a key input to a wide range of business and strategic decisions. The framework, supported by risk policies and business standards, sets out the areas where economic capital management information must be used as part of decision-making and risk management processes. This ensures that requirements to use economic capital are embedded within the relevant processes including, but not limited to, strategy and planning. Economic capital is calculated using the IM or through the SF calculation, and aggregated to determine the Company's economic capital requirement using its PIM.

B.3.4 Governance of the IM

The CRO is the ultimate owner of the IM; the day-to-day responsibilities are delegated to the Chief Risk Actuary. The Chief Risk Actuary gives assurance to the Risk Committee that the IM is appropriate for use on an ongoing basis. He also confirms the IM adequately reflects the Company's risk profile, is accurate and works effectively.

The SII IM and Data Governance Business Standards are part of the overall Risk Management Framework. These combine to ensure that the Company operates within a controlled environment when developing methodologies and assumptions and when running processes and systems.

The Risk Committee is responsible for approving any IM changes before submission to the College of Supervisors for approval. The quarterly model change reports and supporting evidence provide the required information to support Risk Committee and the College of Supervisors' approval.

There has been no material change to the governance of the IM during 2016.

Validation process

The Company's IM is validated by testing the individual calibrations and methodologies that are input into the model and the results that are output from the model. The validation tests applied comprise both mathematically defined tests and those based on qualitative judgement. Key tests include benchmarking, back-testing and sensitivity testing. The validation tests are run, documented and assessed against criteria which are designed to draw conclusions on the appropriateness of the IM.

The Internal Model Independent Validation (IMIV) Business Standard defines the scope of IMIV and the approach to each independent validation exercise is approved by the Board. The Enterprise Risk Director reviews the findings of the exercise and provides an opinion to the Risk Committee as to whether the IM is suitably accurate and fit for purpose, and whether it is recommended for approval by the Board.

B.4 Internal Control System

B.4.1 System of Internal Control

The Company's principles for ensuring effective internal control are set out in the Risk Management Framework and, in particular, the Internal Control Business Standard. These include:

- An appropriate "tone from the top". This supports the effective management of exposures, adequate resourcing, effective communication, malpractice reporting, a business ethics code that is annually signed up to by employees, and a commitment to integrity, ethical behaviour and compliance.
- A clear organisational structure that supports the system of internal control and includes the effective operation of an adequately resourced three lines of defence model, appropriate and proportionate segregation of duties, a clear system of delegated authorities, clearly defined roles and responsibilities for staff, and the consideration of risk management and control responsibilities when setting objectives for and reviewing the performance of all staff.
- Implementation of Risk Policies and Business Standards, and consistent IMMMR of all risks.
- Effective controls for each of its core business processes which are regularly monitored and reported on.
- A risk oversight process that provides adequate challenge to the completeness and openness of internal control and risk assessment.

B.4.2 Compliance Function

The primary purpose of the Compliance Function is to assess and manage exposure to regulatory risk. The Compliance Function is an integral part of the Risk Management Framework and constitutes a key part of the Company's corporate governance, including relationships with the FCA and the PRA, and other regulatory bodies. The function is a critical contributor to the safe and sound operation of the Company and underpins the achievement of its strategy and business goals. The key processes that comprise the Company's compliance activity are:

- Conduct regulatory risk management (including monitoring regulatory developments), performed by the Compliance Function and including activities such as;
 - Setting conduct and financial crime policy framework;
 - Providing advice, support, guidance and challenge on conduct and financial crime risk; and
 - Managing conduct and financial crime regulatory engagement.
- Prudential regulatory risk management (including monitoring regulatory developments), performed by the Risk Function and including activities such as;
 - Setting prudential regulatory risk policy framework;
 - Providing advice, support, guidance and challenge on prudential regulatory risk; and
 - Managing prudential regulatory engagement.
- Legal developments monitoring, performed by the Legal & Company Secretarial Function.

Through these processes the Compliance, Risk and Legal Functions also take responsibility for reporting information to the Board and its committees. The oversight of conduct risk has remained a key focus of the Conduct Committee during 2016. The Committee receives a report from the CRO at each meeting which covers any material concerns regarding conduct risk and the treatment of customers generally, along with details and an assessment of the adequacy of management's response.

The CRO has responsibility for prudential and conduct regulatory risk management, whilst the General Counsel is responsible for monitoring legal developments. Those carrying out compliance activities have authority to review all areas of the Company and have full, free and unrestricted access to all activities, records, property and personnel necessary to complete their work, where appropriate.

B.5 Internal Audit Function

The Company's Internal Audit Function is led by the Internal Audit Director who reports directly to the Group Chief Audit Officer and to the Chairman of the Company's Audit Committee.

The Internal Audit Function provides regular reports to the Company's Audit Committee on the robustness of the Company's Risk Management Framework and the appropriateness and effectiveness of the system of internal control. In doing this it considers the adequacy of the Company's system of internal control to manage its business risk and to safeguard its assets and resources. It also considers the effectiveness of any actions put in place by management to address any deficiencies that might exist in the system of internal control.

The Internal Audit Function investigates and reports on cases of suspected financial crime and employee fraud and malpractice, and undertakes designated advisory projects for management.

Independence and objectivity

The Internal Audit Function maintains its independence and objectivity by reporting directly to the Group Chief Audit Officer and the Chairman of the Company's Audit Committee. The Audit Committee has a duty to recommend the appointment or dismissal of the Internal Audit Director to the Board and to participate, jointly with the Chief Audit Officer or designee, in the determination of the objectives of the Internal Audit Director and the evaluation of his levels of achievement, including consultation with the CEO.

The Internal Audit Director proposes a budget which ensures that Internal Audit has sufficient skills and resources to discharge its responsibilities. Internal Audit is authorised to review all areas of the Company and has full, free, and unrestricted access to all activities, records, property, and personnel necessary to complete their work.

Internal Audit Function staff have no direct responsibility for any operational activities. There is a formal policy of rotating staff to ensure that independence is maintained. There is also a restriction on the audits that staff who have previously worked elsewhere in the Company can perform. The Internal Audit Function cannot perform any projects for management that will threaten its actual or perceived independence and objectivity.

An annual declaration of independence is signed by all members of the Internal Audit Function's staff.

B.6 Actuarial Function

The Actuarial Function is accountable for actuarial methodologies and calibrations, plus the resultant Best Estimate Liabilities and capital requirements. It also considers the appropriateness of the IM, supports the IM validation exercises and maintains the IM change log. The Actuarial Function produces an annual report to the Board providing all of the information necessary for the Company's Board to form their own opinion on the adequacy of Technical Provisions and on the Company's underwriting and reinsurance arrangements.

The independence of the Actuarial Function is derived through its membership in the wider Risk Function. The Actuarial Function is led by the Chief Risk Actuary, who reports to the Company's CRO. Persons employed in certain specific roles within the Actuarial Function are subject to the Fit and Proper policy requirements to ensure they have the requisite skills and knowledge to complete their responsibilities. (Fit and Proper requirements are considered in section B.2.)

The Actuarial Function has the authority to review all areas of the Company and has full, free and unrestricted access to all activities, records, property and personnel necessary to complete its work.

B.7 Outsourcing

Policy

The Procurement and Outsourcing Business Standard contains information on the Company's outsourcing policy, setting out the relevant responsibilities, objectives, process, and monitoring arrangements to be applied in cases of outsourcing, all of which shall be consistent with the overall strategy. The standard applies equally to any externally or internally (intra-group) outsourced activity. The objective of this standard is to ensure that minimum control objectives and controls for supplier related activities are followed by all elements of the business, to ensure that supply risk is managed effectively, customers are being treated fairly and continue to receive good outcomes, as well as mitigating potential financial, operational, contractual, and brand damage caused by inadequate management.

The standard aligns with UK regulatory expectations, the FCA, the PRA, and the SII framework and where appropriate, regulatory guidance will be applied as a requirement. The standard applies to all staff involved in supplier related activities and provides direction to staff on their roles and responsibilities in effectively managing supplier activity. It provides clarity on the definition of outsourcing, including where activity is delegated to an intermediary, and whether a function or activity outsourced is assessed as critical or important. All staff have a responsibility to comply with this standard if they are involved with supplier related activity.

The Board has approved the objectives and controls in the standard which cover the following areas:

- Supply governance: business oversight of operational performance for sourcing and supply management activities;
- Sourcing: how a service provider of suitable quality is selected;
- Supplier contracting and approvals: financial, commercial and legal approval of contracts; and
- Supplier management and business continuity: risk based approach to management of supply contracts.

Critical or important outsourcing will attract the highest level of rigour, including regulatory notification, performance and relationship reviews, regulatory compliance review, risk and control assessments.

Critical and important outsourced functions and activities

The Company outsources a range of activities consistent with its outsourcing strategy. These include elements of underwriting, customer contact including claims handling, IT, accounting services, property services and investment management. Critical or important operational activities outsourced include handling of mobile device and travel insurance claims and provision of data centres.

Jurisdiction of service providers

Critical or important outsourced activities are carried out mostly in the UK, but also in several other jurisdictions. The latter includes handling of mobile device insurance claims for business sold in the EU but outside the UK, international claims predominantly in the location of the insured risk and support functions in India and Sri Lanka. Investment management services are outsourced within the Group in the UK.

B.8 Any Other Information

The Company has no other material information to disclose.

Aviva Insurance Limited

Solvency and Financial Condition Report

2016

C. Risk Profile

In this Chapter

- C.1 Underwriting Risk
- C.2 Market Risk
- C.3 Credit Risk
- C.4 Liquidity Risk
- C.5 Operational Risk
- C.6 Other Material Risks
- C.7 Any Other Information

C. Risk Profile

The 'Risk Profile' section of this report provides information on the key risks encountered by the Company as well as the corresponding processes for monitoring the risk exposures and the techniques in place for mitigating these risks. Comments have been included in the following sections to highlight where the Company is exposed to underlying risk arising from ACI.

C.1 Underwriting Risk

C.1.1 Exposure

The Company's exposure to non-life (including health similar to non-life) insurance underwriting risk arises from:

- Inadequate claims reserving assumptions;
- Unforeseen fluctuations in the timing, frequency and severity of claims and claim settlements relative to expectations;
- Unexpected claims arising from a single source;
- Inaccurate pricing of risks or inappropriate underwriting of risks when underwritten; and
- Inadequate reinsurance protection or other risk transfer techniques.

The Company does not underwrite life insurance business, or health products similar to life insurance. Longevity risk, associated with bodily injury claims settled as PPOs, is reinsured with Aviva Annuity UK Limited, a fellow Group Company. The Company also has an inwards adverse reserve deterioration agreement with its subsidiary undertaking, The Ocean Marine Insurance Company Limited (Ocean Marine) (see section C.3.2).

The Company has a preference for general insurance risk in measured amounts for explicit reward, in line with its core skills in underwriting and pricing. This includes risks ceded to the Company under an inwards reinsurance arrangement with its subsidiary undertaking, Gresham Insurance Company Limited (Gresham) with effect from 1 January 2006 whereby 100% of premiums, claims and expenses are reinsured by the Company.

On 1 January 2016, the Company increased its 5% retrospective (both new and existing business) quota share reinsurance arrangement with AIIL to 50%. Further details are provided in section A.4.1. The Company's profile of underwriting risk has otherwise remained relatively stable during the year.

In February 2017, the UK Ministry of Justice announced a change to the Ogden discount rate, which is used in calculating awards for claims involving future care costs or loss of earnings. Further details are provided in section A.1.2. The change in Ogden rate affects underwriting risk exposure due to larger lump sum bodily injury claims. In addition, there is an expectation of an increase in the number of claims settling on a lump sum basis, with fewer claims expecting to settle as a PPO.

The Company's overall exposure to underwriting risk is measured using the SCR. QRT S.25.02 (Appendix F.1.7) shows that the Company's undiversified SCR for underwriting risk is £0.6bn. Underwriting risk is also measured and monitored in terms of Best Estimate Liabilities, total sum insured and estimated maximum loss. Estimated maximum loss is an estimation of the maximum loss that could be reasonably sustained as a result of a single incident considered to be within the realms of probability.

C.1.2. Risk concentration

The Company avoids underwriting risk concentration through its scale, geographical distribution of underwriting risks, diversity of product lines and diversity of distribution channels. Individual risks and groups of risk are only accepted if, after diversification and reinsurance, the residual risk is within appetite. Controls are in place to ensure accumulations of risk are identified, evaluated and controlled.

The Company's general insurance risk is primarily located in the UK and Ireland and its most concentrated non-life underwriting peril is North European Windstorm. The Company is also exposed to the underlying general insurance risk arising from its principal subsidiary ACI. This is managed locally but is captured within the Company's SCR. The most concentrated non-life underwriting peril in Canada is British Columbian Earthquake.

C.1.3 Risk mitigation

The Company manages its exposure to general insurance risk through the application of controls frameworks that include:

- Claims reserving that is undertaken by actuaries and is also subject to periodic external review;
- Risk appetites to limit exposures to key general insurance risks;
- Extensive use of data, financial models and analysis to improve pricing and risk selection;
- Underwriting limits linked to delegations of authority that govern underwriting decisions;
- Product development in a management framework that ensures products and propositions meet customer needs;
- Product limits and exclusions;
- Governance of outsourced functions writing products on behalf of the Company; and
- Documented claims management philosophies and procedures.

The primary technique used to mitigate underwriting risk is reinsurance. Reinsurance is purchased to mitigate underwriting risk and maintain exposures within appetite. In some cases, the Company participates in Group reinsurance programmes, which leverage economies of scale whilst allowing the Company to trade to the full extent of its underwriting appetite.

The Company and its subsidiaries have a number of reinsurance arrangements in place, with both internal and external counterparties, to mitigate underwriting risk. Major reinsurance arrangements include:

- Catastrophe reinsurance providing protection against the risk of natural hazard events (e.g. earthquake, windstorm);
- Reinsurance of most of the Company's legacy UK latent claims reserves;
- Reinsurance of the legacy London Market claims reserves of the Company's Ocean Marine subsidiary;
- Reinsurance of longevity risk, on the Company's bodily injury claims settled as PPOs;
- The 50% quota share reinsurance arrangement, covering both the Company's new and existing business, with the Group's onshore risk retention vehicle AIIL. Further details are provided in section A.2.3;

- Reinsurance of specific flood risks to Flood Re Limited;
- Reinsurance of terrorism risk to Pool Reinsurance Company Limited;
- Casualty excess of loss reinsurance providing protection against the risk of large losses arising from motor liability or general liability insurance; and
- Property excess of loss reinsurance providing protection against the risk of large losses arising from property insurance.

Reinsurance purchases are reviewed to verify that the levels of protection being bought reflect any developments in exposure and the risk appetite of the Company. The basis of these purchases is underpinned by extensive financial and capital modelling and actuarial analyses which consider the cost and capital efficiency benefits. This may involve utilising externally sourced probabilistic models to verify the accumulations and loss probabilities based on specific portfolios of business. In addition to external models, scenarios are developed and tested using Company data to determine potential losses and appropriate levels of reinsurance protection. Reinsurance covers single large exposures and concentrations of exposures. The Company has processes in place to manage catastrophe risk and purchases catastrophe reinsurance to protect against significant natural and man-made hazard events.

The management of insurance risk is overseen by specific senior management committees, namely the ALCO, the Insurance Committee and the Reserve Committee.

C.1.4 Stress and scenario testing and sensitivity analysis

Descriptions of the methods used, assumptions made and outcomes of SST and sensitivity analysis are provided in section C.7.1.

C.1.5 Special purpose vehicles

The Company has not transferred underwriting risk to special purpose vehicles, as defined by the SII Directive.

C.2 Market Risk

C.2.1 Exposure

The Company's exposure to market risk arises from the risk of adverse financial impact resulting directly or indirectly from fluctuations in interest rates, property prices, foreign currency exchange rates and inflation. Market risk arises due to fluctuations in both the value of liabilities and the value of assets held. In addition to its own risks, the Company's SCR also includes the underlying risks of its subsidiaries, including its principal subsidiary ACI.

Interest rate risk arises primarily from the Company's fixed income securities and liabilities, which are exposed to fluctuations in interest rates. The Company seeks to match assets to liabilities and uses interest rate derivatives to meet its interest rate appetite.

Property price risk arises from the Company's investments in investment property and property investment vehicles. Property price risk is accepted by the Company, within appetite, to drive investment return as part of the Company's investment strategy.

The Company is exposed to inflation risk where there is a mismatch between assets and liabilities that are sensitive to inflation. Retail Prices Index (RPI) elements of inflation risk are monitored and managed through asset-liability matching and hedging where appropriate in accordance with the agreed risk appetite.

The Company's material exposure to foreign currency risk arises primarily from its investment in ACI, the business of its Irish branch, and the growth of international Corporate and Specialty Risk (CSR) business lines. The Company seeks to match non-sterling liabilities from its Ireland and international CSR business using a combination of non-sterling assets and currency derivatives to ensure liabilities in non-domestic currency can be settled as they fall due. The Company also seeks to mitigate the impact of foreign currency risk to its regulatory surplus (denominated in sterling) by using currency derivatives to hedge the contribution of ACI (denominated in Canadian Dollars (CAD)) to sterling.

There has been no material change in The Company's overall market risk exposure during the period, however underlying this there have been offsetting movements in the Company's sensitivity to interest rate risk and inflation risk: the reduction in the PPO propensity associated with the decrease in the Ogden discount rate has reduced sensitivity, whilst falling real yields and other changes in liabilities increased sensitivity.

Foreign currency exchange rate risk exposure increased during the year due to an increase in the relative value of the Canadian subsidiary.

The Company's overall exposure to market risk is measured using the SCR. QRT S.25.02 (Appendix F.1.7) shows that the Company's undiversified SCR for market risk is £0.8bn. This includes credit risk in respect of the Company's bond holdings whose risk profile and management is described in section C.3. In addition to the SCR, a number of risk-specific metrics are used to monitor market risk at granular level:

- Key interest rate, RPI, and currency related parameters;
- Changes in the price level of individual assets or specific asset classes, for example property prices.

C.2.2 Risk concentration

The Company monitors its investment exposures in aggregate across all classes of financial instruments (debt securities, equities, derivatives and other investments), to individual issuers, geographies, sectors, and asset classes.

The Company's largest foreign currency exposure is to the CAD which constitutes 21% of the Company's Own Funds.

The valuation of assets and liabilities are materially impacted by movements in market-implied interest rates and inflation, with those risks being managed within pre-defined risk appetites using a combination of asset-liability matching and derivatives.

C.2.3 Risk mitigation

The Company manages market risk within its market risk framework, within local regulatory constraints and in line with established Group policy, including minimum principles for matching liabilities with appropriate assets. As described in section C.2.1, the Company monitors exposures to market risks and uses derivatives to mitigate interest rate, inflation and foreign currency exchange rate risks.

The Company only uses derivatives to reduce risks and facilitate efficient portfolio management. Risks arising from use of derivatives for hedging purposes include basis risk, which is the risk of an unexpected adverse financial impact arising because the exposure covered by a risk-mitigation technique, such as hedging using derivatives, does not correspond to the Company's risk exposure. The Company controls derivative basis risk by applying strict controls to its processes for their administration and valuation. The Company's control framework for derivative risk is consistent with market and industry practice.

In accordance with the requirements of its Financial Risk Mitigation Business Standard, the Company assesses and documents the effectiveness of arrangements to mitigate market risk. This assessment is initially undertaken prior to deciding whether or not to enter into an arrangement, and considers the impact of the proposed arrangement on key metrics including:

- Risk measures, primarily economic capital; and
- Financial measures, including cash flow, IFRS operating profit, liquidity and expenses.

If the initial assessment indicates that the impact on key metrics is material, further assessments are carried out at regular intervals throughout the duration of the arrangement. These assessments typically include stress testing and sensitivity analysis. Transactions to mitigate the same risk may be considered in aggregate (e.g. programmes to mitigate interest rate risk or foreign exchange risk).

The Company conducts on-going monitoring of the effectiveness of market risk mitigation techniques by reporting management information and analysis to the ALCO, and the Board's Risk Committee. Processes are also in place to monitor key economic data against pre-defined trigger points to enable appropriate oversight and actions to take place if economic conditions deteriorate, as set out in the Company's pre-prepared contingency plans.

C.2.4 Stress and scenario testing and sensitivity analysis

C.3 Credit Risk

C.3.1 Exposure

The Company's exposure to credit risk arises from the risk that it will incur a financial loss from the default or failure of third parties to meet their payment obligations to the Company, or variations in market values as a result of changes in expectations related to these risks. In addition to its own risks, the Company's SCR also includes the underlying risks of its subsidiaries, including its principal subsidiary ACI.

The Company's approach to managing credit risk recognises that there is a risk of adverse financial impact resulting from fluctuations in credit quality of third parties including default, rating transition and credit spread movements. The Company's credit risks arise principally from exposures to debt securities, loans, insurance debtors, reinsurance counterparties and other assets such as bank deposits and derivative and securities financing counterparties.

The Company's management of credit risk includes implementation of credit risk management processes (including limits frameworks), and detailed reporting and monitoring of exposures against pre-established risk criteria. The management of credit risk is overseen by the Company's ALCO.

Risk mitigation techniques are used where and when deemed appropriate. These are utilised where possible to remove residual unwanted risks, as well as to bring or keep exposure limits within appetite, and include methods such as collateralisation and funds withheld arrangements.

There has been no material change in the Company's credit risk exposure over the reporting period. Whilst there has been a material increase from 5% to 50% in the quota share arrangement with AIIL, credit risk has been materially mitigated by operating a funds withheld arrangement on a significant proportion of the balance due to AIIL.

The principal basis used to measure the Company's exposure to counterparty risk is the SCR. QRT S.25.02 (Appendix F.1.7) shows that the Company's undiversified SCR for counterparty risk is £0.1bn. Counterparty risk relates to the risk associated with reinsurers and insurance debtors. The Company is additionally exposed to the credit risk associated with investment bond holdings included in the market risk SCR reported in the QRT as described in section C2.1. The following metrics are also used by the Company when measuring and assessing its credit risk exposure and to support risk management actions and investment decisions:

- Maximum exposure: credit exposure of the Company's financial assets to counterparties;
- External credit rating: available Moody, Standard & Poor and Fitch ratings;
- Market adjusted credit ratings: external credit ratings modified for the market price of the counterparty's credit default swap;
- Internal credit ratings: determined for broker counterparties that are not externally rated, using methodologies broadly consistent with those used by external rating agencies.

The overall credit quality of the Company's financial investments is strong. At 31 December 2016, investment grade debt securities (external credit rating AAA to BBB) comprised 99.8% of total debt securities. Similarly, reinsurance assets with external credit ratings of AA to A comprised 98.5% of total reinsurance assets.

C.3.2 Risk concentration

The Company's credit limit framework restricts investment in individual issuers, geographies, sectors, and asset classes to ensure the Company is not exposed to significant concentrations of credit risk.

The Company's main concentration of external credit risk arises from holding UK government debt securities. At 31 December 2016 the Company held £1,624m of UK government debt. The Company's biggest industry sector exposure is to worldwide bank debt securities (£652m). The majority (71%) of the Company's holding of bank debt securities is in senior debt.

The Company's largest external reinsurance counterparty is Swiss Reinsurance Company Limited (including its affiliated companies). At 31 December 2016, the largest external reinsurance asset recoverable is £815m. This exposure is reduced by collateral comprising a portfolio of highly rated assets amounting to £206m.

The Company's largest intra-group reinsurance counterparty is AllL. At 31 December 2016, the reinsurance asset recoverable from AllL (excluding unearned premium reserve) is £2,355m. Credit risk is reduced by a withheld funds arrangement, whereby the Company holds a balance equal to the higher of IFRS or SII Technical Provisions of the reinsured business.

As part of the restructuring in 2013, the Company entered into a loan of £5.8bn to AGH, the Company's immediate parent. The loan is secured on the UK Life business and a number of the Group's non-UK operations, and has a final maturity date of December 2042. During the year, the loan balance has been reduced by £900m to £1,513m at 31 December 2016. The reduction was settled via set-off of dividends declared to AGH.

The Company has an inwards adverse reserve deterioration agreement with its subsidiary undertaking, Ocean Marine. This agreement provides Ocean Marine with an extra £1bn of reinsurance cover to protect against circumstances in which its reinsurance arrangement with National Indemnity Company (NIC) is exhausted or otherwise fails to satisfy claims. Ocean Marine's reinsurance arrangement with NIC provides substantial protection in excess of its current gross insurance liabilities.

The Company has an arrangement with Aviva Annuity UK Limited, a fellow Group company, for the outwards reinsurance of its obligations in respect of PPOs. At 31 December 2016, the reinsurance asset recoverable from Aviva Annuity UK Limited is £575m. The credit risk exposure is mitigated by a funds withheld arrangement. The Company retains legal title of the assets backing the reinsured liabilities whilst Aviva Annuity UK Limited retains beneficial ownership. The funds withheld are maintained quarterly to match the reinsurance asset.

In April 2015, following the partial return of capital on the Company's equity investment in ACI, the Company returned the proceeds back to ACI in the form of a subordinated unsecured loan of CAD 350m. The loan, with a carrying balance of CAD 350m, has a final maturity date of March 2045. In the event that ACI's minimum regulatory capital requirement falls below certain local trigger levels, ACI may redeem the loan in exchange for issuing equity whose aggregate value is equal to the principal amount outstanding on the loan.

In June 2016, the Company entered into a subordinated unsecured loan from AGH of CAD 480m and used the proceeds to provide a subordinated unsecured loan to ACI of CAD 480m; both arrangements have a final maturity date of 2046.

C.3.3 Risk mitigation

As described in section C3.1 and C.3.2, the Company has in place a credit control framework to manage credit risk, and uses techniques including collateralisation and withheld funding arrangements to mitigate unwanted credit risk.

In accordance with the requirements of the Group Financial Risk Mitigation Business Standard the Company assesses and documents the effectiveness of arrangements to mitigate credit risk. On-going monitoring is carried out by reporting management information to the ALCO and the Board's Risk Committee, against pre-defined trigger points, to enable appropriate oversight and to prompt action if effectiveness deteriorates, as set out in the Company's pre-prepared contingency plans.

C.3.4 Stress and scenario testing and sensitivity analysis

C.4 Liquidity Risk

C.4.1 Exposure

The Company's exposure to liquidity risk arises from the risk that its liabilities cannot be settled, in a timely and cost-effective manner, as they fall due because of insufficient liquid assets. Liquidity risk may arise from uncertainty of the value and timing of liabilities or the ability to realise assets to produce cash to meet obligations. The Company assesses liquidity risk under a range of scenarios and various levels of liquidity stress. Sources of liquidity risk include:

- Insurance underwriting e.g. catastrophe claims arising from adverse weather events;
- Variances of actual operational cash flow from shorter-term forecasts; and
- Other cash flow volatility e.g. derivative and collateral calls arising from the Company's risk mitigation activities.

The principal bases used to measure and assess the Company's exposure to liquidity risk are liquidity coverage ratios, absolute liquidity coverage relative to pre-defined appetites and the quantum of certain liquid assets. Liquidity coverage ratios measure the extent to which available liquidity is sufficient to meet expected liquidity requirements following an extreme liquidity-specific stress event over short-term and long-term stress scenarios. The short-term and long-term liquidity risk appetites were introduced in April 2016 and June 2016, respectively. Liquidity is also monitored in the event of a stressed run-off of the Company's liabilities following closure to new business and managed within the Company's Stressed Run-Off Liquidity risk appetite.

The Company's liquidity profile was maintained within appetite on both absolute and stressed liquidity coverage ratio bases, over short- and long-term scenarios, and under stressed run-off basis throughout the year.

Stressed run-off liquidity profiles improved over 2016 due to the impact of the quota share reinsurance arrangement with AIIL. Other liquidity requirements remained within appetite throughout the year.

C.4.2 Risk concentration

The credit limit framework described in section C.3.2 above also avoids concentrations of liquidity risk by preventing investment in a restricted number of issuers, asset classes and sectors. The Company has set its investment strategy to ensure it has sufficient liquid funds to meet its expected obligations as they fall due. The diversity of sources of liquidity available to the Company averts concentration of liquidity risk.

C.4.3 Risk mitigation

The Company manages its liquidity risk by considering the liquidity impact before accepting new risks and managing its existing liquidity profile by:

- Daily monitoring of projected short-term cash flow needs;
- Setting an investment strategy which reflects liquidity requirements and the potential liquidity profile of liabilities;
- Setting liquidity risk appetites which require that sufficient liquid resources be maintained to cover net outflows in a stress scenario over a range of timeframes;
- Defining trigger levels that enable action to be taken before those levels are breached; and
- Maintaining a liquidity risk management plan which details management actions to address liquidity funding requirements in a significant stress scenario.

The Company has access to a contingent facility that provides up to £500m of cash in the event of a shortfall in the Company's SII economic capital and/or its position against its Stressed Run-Off Liquidity risk appetite. The facility is collateralised by a range of highly rated banks and is guaranteed by AGH. In extreme circumstances, the Company could, in addition, approach the Group for additional short-term borrowing whilst the Company liquidated other assets. The Group maintains significant committed borrowing facilities from a range of highly rated banks to mitigate this risk further.

The Company monitors the effectiveness of liquidity risk mitigation techniques as follows:

- The internal controls, that enable effective liquidity risk management, are subject to assurance testing to ensure they
 operate effectively;
- Actual and projected liquid resources, cash inflows and outflows, as well as maturity analyses on insurance liabilities and financial assets, in both normal and stressed scenarios is regularly reported to and monitored, by the ALCO and the Board's Risk Committee, against pre-defined trigger points to enable appropriate oversight and identify any appropriate actions

C.4.4 Expected Profit Included in Future Premium (EPIFP)

The amount of EPIFP, calculated in accordance with Article 1 of the SII regulations and included within the valuation of the Company's Technical Provisions as at 31 December 2016 is immaterial. (See the Own Funds QRT S.23.01, Appendix F.1.6.)

C.4.5 Stress and scenario testing and sensitivity analysis

C.5. Operational Risk

C.5.1 Exposure

The Company's exposure to operational risk arises from the risk of direct or indirect loss, caused by inadequate or failed internal processes, people and systems, or external events including changes in the regulatory environment. The Company has a limited appetite for operational risk and aims to reduce these risks as far as commercially sensible.

Conduct risk, an element of operational risk, is where the Company does not achieve positive or fair customer outcomes. Management of conduct risk was a key priority for the Company across the whole lifecycle of its products and throughout the end to end journey of its customers in 2016 with robust governance and metrics embedded across the organisation.

The Company also seeks to manage its exposure to reputational risk, which is the risk of loss to the Company's franchise value from damage caused to the Company's brands or reputation. Examples of factors, regardless of whether authenticated or not, which could damage the Company's brands or reputation include litigation, employee misconduct, operational failures, the outcome of regulatory investigations, media speculation and negative publicity, disclosure of confidential client information or inadequate services.

The Company's strategy of digital customer interaction, its use of advanced data analytics and the increasing cyber security threat, together with regulators' attention to conduct issues, has increased its inherent exposure to risks such as data theft, conduct breaches and customer service interruption arising from IT systems failure. However, the Company has sought to contain and reduce exposure to these risks during the year, for example investment in a programme to improve IT security, disaster recovery and outsourcing risk. The Company has also implemented an Operational Risk and Control Management Framework, which better integrates the results of the risk identification and assurance activities carried out across the Company's three lines of defence.

Operational risks are initially identified and assessed against implemented controls. Residual risk, outside tolerance, is given prioritised management action to reduce it within tolerance. Operational risk is quantitatively assessed on the basis of financial loss and misstatement. Potential reputational and conduct impacts are qualitatively assessed.

The Company holds economic capital, based on the SII SCR, against residual operational risk, to the extent that it cannot be eliminated by management action. QRT S.25.02 (Appendix F.1.7) shows that the Company's undiversified SCR for operational risk is £0.4bn. The Company also produces specific conduct risk management information used to measure and analyse its exposure to conduct risk.

There have been no material changes in the operational risks that the Company is exposed to over the year.

C.5.2 Risk Concentration

The Company's scale and business model as a multi-business line, multi-geography and multi-channel business, creates diversification of risks and generally helps to reduce concentrations of risks particularly when risks across the Company and its subsidiaries are aggregated.

The Company's operations are spread across a number of office locations that are geographically well spread, which would help ensure continuity of service in the event of catastrophe.

The majority of the Company's products are sold under the 'Aviva' brand, enabling leverage on the strength of the brand and supporting delivery of the Company's business strategy. The Company is therefore vulnerable to any operational failures that adversely impact public perception of the 'Aviva' brand.

C.5.3 Risk mitigation

Operational risks are considered by the Company to be preventable and are managed through business controls. The Company's operational risk strategy is to improve its business processes to:

- Reduce operational risk and associated losses, thereby improving cost to income ratio and variability in financial performance;
- Improve customer outcomes and employee satisfaction; and
- Sustain customer confidence and a positive regulatory reputation.

The Company's business standards set out the minimum control objectives and controls that each business area is required to operate. Operational risk tolerances are quantitative boundaries that constrain specific risk-taking activities at an operational level.

The Company records and analyses operational risk events to ensure remedial action is taken, lessons are learnt and, if the event impacts customers, they are treated fairly. This includes risk events that do not give rise to a financial loss, such as near misses or fortuitous gains. This assessment enables the Company to highlight areas for improvement, implement corrective actions to avoid recurrence, and improve its understanding of operational risk.

The Company has identified business critical functions and has exit and termination plans and business continuity and disaster recovery plans in the event of supplier failure. These plans are reviewed at least annually.

The Company's three lines of defence all monitor the effectiveness of the controls that are in place against operational risk. Further details of the three lines of defence are included in section B.4.1, including the specific roles and responsibilities of each line. Operational risk is overseen by the Operational Risk Committee, which is a senior management committee, and the Board's Risk Committee.

C.5.4 Stress and scenario testing and sensitivity analysis

C.6 Other Material Risks

The Company has no material information to disclose regarding other material risks.

C.7 Any Other Information

C.7.1 Stress and scenario testing and sensitivity analysis

SST is a fundamental element of the Company's Risk Management Framework which is embedded within the Company's decision-making, strategy and Plan activities. SST provides insight into key risk exposures and dependencies of the Company; considering resilience of potential changes to these exposures and dependencies; and anticipating a range of possible outcomes. The evaluation of the potential impacts on the Company's capital and/or liquidity positions enables the Company to identify and prepare for appropriate ways to mitigate and/or manage the realisation of such impacts.

There are two main components of SST: (1) sensitivity analyses which consider single factor standalone impacts at a point in time to changes in economic and non-economic assumptions and (2) scenario analyses which consider impacts from a series of potential events.

The Company's stress and scenario methodology is based on the following stages:

- Identify existing and emerging risks;
- Measure resilience to stress events and scenarios;
- Monitor the impact of the potential stress events and scenarios on actual and projected capital and liquidity positions;
- Manage the potential stress events and scenarios by setting risk appetites and defining management and recovery actions; and
- Report to the Company's ALCO, Risk Committee, Board and/or the PRA.

C.7.1.1 Stress and scenario testing

At least annually, a broad range of Company risk specific stress and scenario tests are defined in consultation with key stakeholders to assess the impact of a range of potential events of differing levels of severity on the capital and/or liquidity positions of the Company. The stress and scenario tests performed by the Company, during 2016, included adverse economic conditions, catastrophic events, reserve deterioration and operational failings.

A range of assumptions are made in the development of potential events and the measurement of resilience to such events. These assumptions are defined by suitable experts and, where applicable, by the Regulators.

The outcome of the 2016 Company's SST serves to illustrate that the Company is resilient to a wide range of potential events and that the Company has a variety of plausible management actions that could be executed in a timely manner, to mitigate the potential impact(s) from Company specific or market-wide events.

C.7.1.2 Sensitivity analysis

Management use the sensitivity analyses to assess the impact of a range of potential events of differing levels of severity on the capital and/or liquidity positions of the Company and to ensure that the Company has a sufficient range of plausible management actions that could be executed in a timely manner to mitigate the potential impact(s).

The SCR is the primary basis used by the Company to measure and assess its risks. The sensitivity analysis performed by the Company therefore includes consideration of the sensitivity of its SCR cover ratio to a range of economic assumptions.

The table below shows the absolute change in cover ratio under each sensitivity, e.g. a 3% positive impact would result in an increase in the cover ratio by 3%.

Sensitivity to Assumptions ¹	Impact on cover ratio ²
Economic Assumptions	
25bps increase in Interest Rates	4%
25bps decrease in Interest Rates	(4%)
50bps increase in GBP Corporate Bond Spreads	1%
50bps decrease in GBP Corporate Bond Spreads	(1%)
50bps increase in GBP Sovereign Bond Spreads	(3%)
50bps decrease in GBP Sovereign Bond Spreads	3%
50bps increase in GBP Inflation Rate	(2%)
50bps increase in GBP Inflation Rate	2%
Non-Economic Assumptions	
10% increase in Maintenance and Investment Expenses	(6%)
5% increase in Gross loss ratios	(13%)
5% increase in Reserves	(22%)

¹Sensitivities are provided for the Company unless otherwise stated

²Represents regulatory view

Limitations of the sensitivity analyses

The table above demonstrates the effect of a change in a key assumption while other assumptions remain unchanged whereas in reality, sensitivities are dynamic in nature as they will vary in quantum due to interactions with other risks and changes in values of those risks.

Other limitations in the sensitivity analyses include:

- The economic assumptions are hypothetical market movements selected to represent the Company's view of possible near-term market changes but which cannot be predicted with certainty.
- The sensitivities are non-linear, and larger or smaller impacts cannot be interpolated or extrapolated from the outcome.
- It is assumed that all interest and inflation rates move in an identical fashion.
- Movement in bond spreads includes the impact of volatility adjustments.
- The sensitivity analyses do not take into consideration active management of the Company's assets and liabilities, noting that the Company's financial risk management strategy, for example, aims to manage the Company's exposure to market fluctuations.
- The diversification benefit across the UK and Canadian components of the Company has not been factored into the 2016 SII cover ratio impacts, this would tend to overstate the cover movement, although not materially.
- As investment markets move past various trigger levels, management actions could include selling investments, changing investment portfolio allocation and taking other protective action.

C.7.2 Prudent Person Principle

The Company ensures that its assets are invested in accordance with the Prudent Person Principle as set out in Article 132 of the SII Directive through the collective application of its risk policies and business standards. These ensure that the Company invests in assets whose risks it can properly identify, measure, monitor, manage, control and report, and appropriately take into account in the assessment of its overall solvency needs having regard to the term and nature of its liabilities. The Company's asset liability management business standard and certain provisions of the investment management business standard contain mandatory requirements to ensure that the Company develops its own set of key risk indicators and takes into account the risks associated with its investments without relying only on the risk being adequately captured by the capital requirements. Risk appetites by risk type are also set and monitored by the Company. Other business standards set requirements for the quality of investment assets (including setting risk limits to control the market and credit risk within a portfolio), matching of assets to liabilities, diversification of invested assets and use of derivatives.

Aviva Insurance Limited

Solvency and Financial Condition Report 2016

D. Valuation for Solvency Purposes

In this Chapter

- D.1 Assets
- D.2 Technical Provisions
- D.3 Other Liabilities
- D.4 Alternative Methods of Valuation
- D.5 Any Other Information

D. Valuation for Solvency Purposes

The 'Valuation for Solvency Purposes' section of the report provides a description of the bases, methods and main assumptions used in the valuation of assets, technical provisions and other liabilities for each material asset and liability class.

The Company's IFRS balance sheet is presented in column (b) of the following table, in accordance with the classification of assets and liabilities used in its financial statements. The references given in column (a) are to relevant accounting policies and notes provided in the financial statements.

A number of reclassifications, required to align the Company's IFRS balance sheet as shown in its financial statements, to the classifications required for the prescribed format of the SII balance sheet QRT, are given in column (c). The most significant reclassifications are:

- Under the SII requirements cash flows relating to reinsurance premium are included within Reinsurance Recoverables, and cash flows relating to premium and policyholder tax are included within Technical Provisions. In the IFRS balance sheet these amounts are included within reinsurance payables, insurance and intermediaries receivables and other liabilities respectively.
- Loans and amounts receivable from, and payable to, Group companies under IFRS, are reclassified within the SII balance sheet to the relevant underlying nature of the balance. A material amount has been reclassified as Loans.
- Investments, including cash equivalents, are reclassified under SII. They also include accrued investment income which is classified within prepayments and accrued income under IFRS.

The Company's assets and liabilities, as valued under IFRS and reclassified in line with SII requirements are shown in column (d). The Company's SII balance sheet is summarised in column (e) and detailed in the balance sheet QRT S.02.01 included in Appendix F.1.1. Differences between the valuation of the Company's assets and liabilities under SII and IFRS are presented in column (f).

Where the valuation of assets and liabilities is the same under IFRS and SII, a description of the bases, methods and main assumptions can be found in the accounting policies and notes of the Company's financial statements. If the valuation is materially different, a description of the bases methods and main assumptions used under SII is given in Sections D.1.1, D.2.1 and D.3.1 below. Where alternative methods of valuation have been used these are detailed in Section D.4.

Assets and other liabilities have been valued, according to the requirements of the SII regulations, at the amount for which they could be exchanged between knowledgeable willing parties in an arm's length transaction. The value of other liabilities is not adjusted to take account of the impact of changes in own credit standing of the Company.

The Company applied the following hierarchy of valuation approaches:

- 1. Quoted market prices in active markets for the same assets or liabilities;
- 2. Quoted market prices in active markets for similar assets and liabilities (with adjustments to reflect differences where necessary);
- 3. Alternative methods of valuation.

The criteria to determine whether a market is active are consistent with IFRS 13 Fair Value Measurement. An "Active market" under IFRS is defined as a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. The assets, classified as Level 1 and Level 2 under IFRS 13, are deemed as market consistent under SII. The assets classified as Level 3, for which there is no active market, are considered to use alternative valuation methods under SII.

In line with SII requirements, the value of the Company's investment in its principal subsidiary, ACI, is included within participations in both the SII and IFRS balance sheets. The investment is not disaggregated into ACI's underlying assets, Technical Provisions and other liabilities. However, when considering the Company's risks and calculating the Company's SCR the underlying risks of ACI and the Company's other subsidiaries are taken into account.

Balance Sheet – IFRS and SII

As at 31 December 2016 £m	Note in financial statements	IFRS balance sheet classified according to financial statements	Reclassification of IFRS balances to SII balance sheet categories	Reclassified IFRS balance sheet	SII balance sheet	Valuation differences between SII and IFRS
	(a)	(b)	(c)	(d) =(b)+(c))	(e)	(f) =(e)-(d)
Goodwill	L & 8	95	-	95	-	(95)
Deferred acquisition costs	X & 16	532	-	532	-	(532)
Prepayments and accrued income	X & 16	157	(157)	-	-	-
Intangible assets	L & 8	158	7	165	-	(165)
Deferred tax assets	BB & 17	129	15	144	117	(27)
Property, plant and equipment (own use)	M & 10	22	-	22	22	-
Property (other than own use)	N & 11	208	-	208	208	-
Participations	C & 9	2,720	-	2,720	1,211	(1,509)
Financial investments						
Equities	Q & 14	7	6	13	13	-
Bonds	Q & 14	4,013	46	4,059	4,059	-
Collective investment undertakings	Q & 14	127	277	404	404	-
Derivatives	Q & 14	117	13	130	130	-
Deposits other than cash equivalents	Q & 14	-	11	11	11	-
Loans	V & 12	5	2,082	2,087	2,087	-
Reinsurance recoverables Receivables	K & 22	5,125	(33)	5,092	4,525	(567)
Insurance and intermediaries	R & 15	1,217	(1,215)	2	2	-
Reinsurance	R & 15	26	-	26	26	-
Trade, not insurance	R & 15	167	361	528	528	-
Amounts due from Group companies	R & 15	280	(280)	-	-	-
Loans due from Group companies	R & 15	2,014	(2,014)	-	-	-
Cash and cash equivalents Other assets	Y & 28	637	(296)	341	341	-
Current tax assets	BB & 17	96	(96)	-	-	-
Group relief assets	17	198	(198)	-	-	-
Other assets			55	55	55	-
Assets		18,050	(1,416)	16,634	13,739	(2,895)
Technical provisions	J & 21	(8,595)	1,286	(7,309)	(6,669)	640
Other provisions	AA & 23	(28)	-	(28)	(28)	-
Deferred tax liabilities	BB & 17	-	(15)	(15)	(18)	(3)
Payables and other financial liabilities						
Deposits from reinsurers	S & 24	-	(2,958)	(2,958)	(2,958)	-
Derivatives	S & 24	(250)	22	(228)	(228)	-
Debts owed to credit institutions	S & 24	(410)	-	(410)	(410)	-
Financial liabilities other that debts owed to						
credit institutions	S & 24	(33)	-	(33)	(33)	-
Insurance and intermediaries payable	S & 24	(71)	-	(71)	(71)	-
Reinsurance payables	S & 24	(45)	28	(17)	(17)	-
Payables trade not insurance	S & 24	-	(285)	(285)	(285)	-
Other payables	S & 24	(24)	24	-	-	-
Amounts due to Group Companies	S & 24	(3,211)	3,211	-	-	-
Loans due to Group Companies	S & 24	(290)	290	-	-	-
Subordinated liabilities		-	(290)	(290)	(290)	-
Other liabilities	25	(799)	103	(696)	(387)	309
Liabilities		(13,756)	1,416	(12,340)	(11,394)	946
Excess of assets over liabilities		4,294	-	4,294	2,345	(1,949)

D.1 Assets

Assets have been valued according to the requirements of the SII Directive and related guidance; the basis of the SII valuation principle is the amount for which they could be exchanged between knowledgeable willing parties in an arm's length transaction. A description of the basis of valuation under SII along with valuation differences between the SII bases and the IFRS financial statements, by asset class, is provided below; if the valuation method has been described in the financial statements, or is an alternative method of valuation detailed in Section D.4, it has not been included in this section.

D.1.1 Goodwill and intangible assets

Goodwill and intangible assets are valued at £nil under SII. The goodwill recognised in the IFRS balance sheet represents the excess of the cost of an acquisition over the fair value of the share of the net assets of the acquired entity at the date of acquisition. The intangible assets primarily consist of internally developed IT systems.

D.1.2 Deferred acquisition costs

Deferred acquisition costs are recognised under IFRS reporting and deferred to the extent they are expected to be recoverable out of future margins in revenues on those contracts. Under SII these are not recognised and are therefore valued at £nil in the SII balance sheet. The associated cash flows are included in the valuation of SII Technical Provisions.

D.1.3 Deferred tax assets

Deferred tax is determined on a non-discounted basis in accordance with International Accounting Standard (IAS) 12, principles on temporary differences between the economic value of assets or liabilities on the SII balance sheet and their tax base.

Assets are recognised to the extent that it is probable that future taxable profits will be available against which they can be utilised. Future taxable profits include taxable liabilities and profits arising from new business. The release of the Risk Margin is not considered to be a source of future profits. Assets are recognised separately to the extent they cannot be offset against corresponding deferred tax liabilities.

The net deferred tax asset arises wholly on unused losses. In addition the Company has unrecognised gross tax losses (excluding capital losses) and other temporary differences of £505m to carry forward against future taxable profits. These trading losses and temporary differences have no expiry date.

The Company also has unrecognised capital losses of £251m. These have no expiry date.

A deferred tax liability arises on unremitted earnings from overseas subsidiaries.

D.1.4 Participations

Under SII participations are valued, using the adjusted equity method, at the Company's share of the excess of assets over liabilities of each entity, valued on a look through basis to the SII value of the assets and liabilities of the entity.

Under IFRS, subsidiaries are stated at their fair values, estimated using applicable valuation models. The fair value is the price that would be received from the sale of the entity, as a whole, in an orderly transaction between market participants at the measurement date. As noted above, under SII participations are valued by looking through to the underlying assets and liabilities of the entity valued on a SII basis.

The reduction in value of participations under SII mainly relates to the Company's investment in its principal subsidiary, ACI.

D.1.5 Reinsurance recoverables

Reinsurance recoverables are calculated as the probability-weighted average of discounted future cash flows relating to reinsurance contracts, adjusted for the expected losses due to counterparty default. Although established separately, reinsurance recoverables are valued on the same basis and using the same methodology and assumptions used to derive Technical Provisions - Best Estimate Liabilities, as described in Section D.2.1, subject to the following:

- Internal expenses are only allowed if they are recoverable under the reinsurance agreement;
- Where the timing of recoveries diverges from that for payments a separate projection is used;
- Allowance for risk of default depends on the credit rating and exposure to the reinsurance counterparty; and
- Reinsurance assets take into account reinsurance commissions.

Reinsurance recoverables, consistent with the calculation of Technical Provisions - Best Estimate Liabilities, includes expected recoveries from pre-inception contracts where they occur within the premium or claims provisions.

Cash flows relating to future reinsurance arrangements comprise both expected recoveries and expected reinsurance premium payments. This means reinsurance contracts which are expected to be written are taken into account and thus assumptions in relation to the likely future reinsurance purchasing decisions are required.

The Company's largest intra-group reinsurance counterparty is AllL. At 31 December 2016 the reinsurance asset recoverable from AllL (excluding unearned premium reserves) is £2,355m. The Company's largest external reinsurance counterparty is Swiss Reinsurance Company Limited (including its affiliated companies). At 31 December 2016 the reinsurance asset recoverable (excluding unearned premium reserves) is £815m.

The material differences between the SII and IFRS valuation bases for reinsurance recoveries are as follows

- Only reinsurance cash flows relating to long tailed claims reserves are discounted under IFRS whereas all reinsurance cash flows are discounted under SII;
- The rate used to discount PPO cash flows is lower under SII than the equivalent rate used under IFRS;
- The unearned reinsurance premium reserve established under IFRS is replaced with a best estimate reinsurance premium provision. This is offset by the release of deferred reinsurance commissions from other liabilities see section D.3.1.
- The SII valuation includes the additional reinsurance premium that is expected to be paid for reinsurance to cover business incepted at the valuation date. This is not accounted for under IFRS.

The Company does not have any Special Purpose Vehicles.

D.1.6 Assets arising from leasing arrangements

Future contractual aggregate minimum lease rentals receivable for investment properties leased to third parties under non-cancellable operating leases are £30m, as at 31 December 2016. Further detail is provided in note 27 to the financial statements.

D.2 Technical Provisions

This section provides a definition of SII Technical Provisions, the methodology and main assumptions used in the valuation of the SII Technical Provisions, the total value of SII Technical Provisions split by material lines of business, a comparison of the valuation of SII Technical Provisions with IFRS Technical Provisions and a description of the level of uncertainty in Technical Provisions.

D.2.1 Valuation of Technical Provisions

Technical provisions which comprise Best Estimate Liabilities and a Risk Margin (unaudited) are summarised in the table below. They are also detailed in the QRT S.17.01 (Non-life Technical Provisions) and S.12.01 (Life Technical Provisions), see Appendix F.1.3.

Whilst the Company only conducts non-life and health (similar to non-life) insurance activities, it has material life insurance obligations in the UK in relation to annuities stemming from non-life insurance contracts (PPO). PPO are classified as Technical Provisions - Life (excluding health and index-linked and unit-linked), within the prescribed format of the SII Balance Sheet.

Line of Business As at 31 December 2016 £m	Best Estimate	Risk Margin (unaudited)	Technical provisions
Medical expense insurance	76	3	79
Motor vehicle liability	2,900	61	2,961
Other motor insurance	165	4	169
Fire and property damage	571	11	582
General liability insurance	1,892	59	1,951
Other	100	1	101
Non-life insurance obligations	5,704	139	5,843
PPOs other than health insurance	706	120	826
Life insurance obligations	706	120	826
Total	6,410	259	6,669

D.2.1.1 Non-life and health (similar to non-life) Best Estimate Liabilities

The following general principles apply to the valuation of Best Estimate Liabilities for non-life and health (similar to non-life) business.

- A Best Estimate is one that represents the expected outcome from the range of possible outcomes for the future and is reasonable and realistic taking account of all the uncertainties involved.
- A consistent approach has been applied across all non-life and health (similar to non-life) business.
- The calculation of Technical Provisions is performed on a going concern basis. This means that it can be assumed that contracts run to their conclusion and as a result a proportion of expected future costs will be covered by future business.
- Business written by intermediaries on a delegated authority basis has been included as if written directly by the Company.

The Company's Best Estimate Liabilities are valued based on the present value of future cash flows discounted using relevant risk-free interest rates. The cash flows that are considered when calculating the Best Estimate Liabilities derive from:

- In-force and expired contracts;
- Contracts that have not yet incepted but that the Company has an obligation to enter into at the valuation date (preinception contracts); and
- Future cancellations or endorsements by the policyholder.

Best Estimate Liabilities comprise a claims provision and a premium provision. The claims provision includes cash flows relating to events that occurred before the valuation date, whether reported or not. The cash flows include premiums, net claims costs and expenses. The premium provision includes cash flows relating to future claim events that have not yet occurred, but that are covered by existing contracts and legally binding pre-inception contracts. The cash flows include premiums, net claims and expenses, in respect of future claim events. Where future premium cash flows are expected to exceed projected future claim and expense cash flows, the premium provision is negative.

When modelling these cash flows the inflows are considered separately from the outflows. Claims costs take into account recoveries from salvage and subrogation. Expenses include administrative, investment management, loss adjustment and acquisition expenses including commissions and premium taxes.

Claims costs

The ultimate cost of outstanding claims is estimated using a range of standard actuarial claims projection techniques. The main assumption underlying these techniques is that the Company's past claims experience can be used as a basis to project future claims. Therefore these methods extrapolate the development of paid and incurred losses, average costs per claim and claim numbers based on the observed development of earlier years. The estimation of ultimate claims costs is done at the level of homogeneous risk groups. These groups are mapped to SII lines of business.

Certain lines of business are also further analysed by claim type or type of coverage. For example latent claims require specialist actuarial techniques appropriate for the nature of the underlying liabilities. Given the long delay between writing the insurance policy and the claim arising, the techniques used for latent claims typically group claims data by the year claims are reported and project the future number and average cost of claims for homogeneous latent claim types based on a combination of own Company experience and industry-wide data. The Company participates on cross-industry working groups to help inform some of the projection assumptions for latent claims.

Qualitative judgement is used to reflect changes in external factors such as public attitudes to claiming, economic conditions, levels of claims inflation, judicial decisions and legislation, as well as internal factors such as portfolio mix, policy conditions and claims handling procedures.

Premium provisions

Premium provisions are estimated by selecting an exposure measure and using that to establish the unearned and pre-inception exposure. Claims cost projections are set for each future period using trends in historic claims data adjusted for known anomalies in the data that are not expected to be repeated in the future, changes in mix and volume of business and to allow for the impact of projected claims inflation. These cost projections are then applied to the predicted exposure to determine the cash flows.

Expenses

Expenses are adjusted for expense and claims inflation and allocated between the claims and premium provisions. They are analysed by homogeneous risk group or at a minimum by SII line of business. Future administrative costs and commission payments are projected using best estimate expense forecasts. Investment expenses are modelled as a percentage of Technical Provisions. Future unallocated loss adjustment expense provisions are set in relation to expected claims levels.

Events Not in Data (ENID)

ENID are events not deemed to be captured by the data which need to be separately allowed for within the best estimate calculations to take appropriate account of uncertainty. Two types of ENID are considered: "known unknowns", which are possible future scenarios that can be anticipated and "unknown unknowns", which are future scenarios that are completely unexpected. No allowance is made for "unknown unknowns" as by definition, they cannot be known or quantified.

Allowances for "known unknowns" are made using scenario analysis to cover any foreseeable event with a potentially material impact. A core list of events is specified which are considered as the starting point for the analysis. ENID are considered both at SII lines of business level, and at portfolio level with allocations to SII lines of business, depending on the scenario being considered.

Discounting

All cash flows are discounted using the appropriate SII yield curve in the relevant currency. The yield curve is based on the risk free rate at the valuation date and is adjusted for the European Insurance and Occupational Pensions Authority (EIOPA) prescribed credit risk adjustment and Volatility Adjustment. Payments are assumed to occur either mid-month or mid-year. Cash flows are modelled in monthly time intervals for the first 10 years and annually thereafter.

Future management actions

There are no future management actions assumed in the calculation of the Company's gross of reinsurance Best Estimate Liabilities as at 31 December 2016. Future management actions assumed in the calculation of reinsurance recoverables are detailed in section D.1.1.

D.2.1.2 PPO Best Estimate Liabilities

The Company's Best Estimate Liabilities for PPO, in common with non-life business, are valued based on the present value of future cash flows discounted using relevant risk-free interest rates. The cash flows that are considered when calculating the Best Estimate Liabilities for PPO derive from:

- Payment of claims benefits: with the majority of PPO providing payments relating to care needs of the claimant, with a smaller number providing loss of earnings payments
- Expenses: these are relatively small (compared to the size of claims benefits) administrative costs in relation to each PPO

PPO Best Estimate Liabilities use life insurance actuarial methods and techniques to estimate appropriate assumptions for each individual claimant.

Discounting

PPO cash flows are discounted using the appropriate SII yield curve adjusted for the EIOPA prescribed credit risk adjustment and Volatility Adjustment. The methods are consistent with those applied to non-life cash flows.

Longevity assumptions

Assumptions are made in relation to the future longevity of each PPO. These assumptions are based on the latest, general mortality assumptions for the population as a whole (including future expected changes in mortality), as well as any impairment to life expectancy on individual PPO based on independent medical opinions.

Inflation assumptions

PPO payments escalate based on indices specified at the time of settlement of the PPO. The majority of PPO claims escalate based on an Annual Survey of Hours and Earnings index (ASHE) with a smaller number escalating in line with the RPI. Assumptions are therefore required for the future escalation of these indices. The Company assumes that, over the longer term, the future escalation of the ASHE indices will be linked to RPI within the UK economy and uses market consistent views of future RPI inflation as the basis to project future ASHE inflation. Adjustments are then made to allow for expected differences between future ASHE inflation and future RPI inflation.

D.2.1.3 Risk Margin (unaudited)

The Risk Margin is an estimate of the amount, in addition to the Best Estimate Liability, that a third party would expect to receive in order to assume ownership of the Company's insurance obligations. The Risk Margin is calculated using a cost of capital approach allowing for diversification between lines of business and is on a net-of-reinsurance basis. The calculation of the Risk Margin is defined as the present value of the cost of capital applied to the SCR in respect of non-hedgeable risks in each future year.

The cost of capital rate is the cost in excess of the risk-free rate, to the third party taking over the liabilities, of raising and holding capital to support the non-hedgeable risks over the lifetime of the business. The same cost of capital rate is used for all insurance companies and is prescribed by EIOPA at 6% per annum.

Discount rate

The rate used to discount the projected non-hedgeable SCR is the basic risk-free rate (including credit risk adjustment), with no allowance for volatility or matching adjustments, where applicable.

Non-hedgeable risk

The SCR in the Risk Margin calculation takes the following risks into account:

- Underwriting risks (non-life, health and life);
- Non hedgeable market risk (except interest rate risk), where it is material;
- Counterparty default risk with respect to reinsurance contracts; and
- Operational risk.

All market risks in respect of investment assets are considered hedgeable. Careful consideration has been given to the extent to which inflation risk in respect of the liabilities should be regarded as hedgeable, consistent with the risk categorisation within the IM. Any inflation risk other than traded price inflation (defined as RPI for UK business and Euro HCIP for Irish business) is regarded as non-hedgeable. This includes the excess of claims inflation over traded price inflation, which is considered within the assessment of insurance risk. There is a deep, liquid and transparent market in the UK for instruments whose value is linked to price inflation and so price inflation risk on the opening Best Estimate Liabilities is considered hedgeable. The additional price inflation risk arising from variation from the Best Estimate Liabilities is not however considered hedgeable.

While reinsurance credit risk, and some underwriting risks, may be hedgeable in practice using credit default swaps etc., the risk margin calculation assumes that these risks are not hedged after the business is transferred to the third party.

Projection of the non-hedgeable risk SCR

In order to project the non-hedgeable SCR which underpins the Risk Margin, simplifications are selected from the hierarchy set out by EIOPA to ensure that the Risk Margin calculation remains proportionate to the nature, scale and complexity of the business.

The projected risks are then aggregated using a correlation matrix approach at each future time period.

Loss absorbing capacity

The loss absorbing capacity of Technical Provisions assumed in the projection of the non-hedgeable risk SCR is consistent with the loss absorbing capacity of Technical Provisions assumed in the calculation of the SCR. No allowance for the loss absorbency of deferred taxes is included in the Risk Margin.

Allocation of the Risk Margin to SII line of business

The Risk Margin is allocated across lines of business using an approximation to the Euler allocation method for IM business units. For SF business units, one of the two prescribed methods is adopted:

- Allocation according to time zero non-hedgeable SCRs.
- Allocation according to present value of non-hedgeable SCRs.

Methodology

In projecting the non-hedgeable risk SCR, the company has adopted an enhanced version of the second approach in the EIOPA hierarchy. The SCR is projected by model calculation class and risk category and allows for an increase in relative volatility as the risks run-off to reflect that smaller portfolios are inherently more volatile.

D.2.1.4 Simplifications

Best Estimate Liabilities

In some areas of the calculation of the SII Best Estimate Liabilities, simplified methods have been used. The simplifications used have been assessed and have no material impact on the value of SII Best Estimate Liabilities. Where simplified methods are used, these are documented and justified in the Company's reserving reports and documentation. The main simplifications within the calculation of SII Best Estimate Liabilities are:

- The majority of the Company Best Estimate Liabilities are in GBP. As part of the calculation of Technical Provisions, the
 Company segments any material exposure to USD and Euro (EUR) currencies. On materiality grounds, exposure to
 currencies outside of GBP, USD and EUR are not separately segmented and are instead converted to GBP at prevailing
 exchange rates.
- Only material inwards reinsurance arrangements are separately modelled.
- The Company's Best Estimate Liabilities include a provision in relation to ENIDs. For the purposes of discounting cashflows, it is assumed that ENIDs have the same cashflow profile as other claims.
- Cashflows are modelled in monthly time intervals for the first 10 years and annually thereafter. For the purposes of discounting, all payments are assumed to occur mid-month or mid-year as dictated by the time intervals used.
- When calculating provisions for potential reinsurer default, reinsurance assets are grouped by reinsurer counterparty
 credit rating and within each credit rating the same probabilities of default are assumed.
- Gross premium debtors are split by class of business and payment date based on the split of written premium.
- The volume of Legally Obliged Unincepted business has been estimated based on a proportion of January's planned written premium for most classes of business. For corporate and speciality type business, the volume has been estimated individually for each class in conjunction with Aviva's underwriting teams to allow for business accepted under long-term agreements.

D.2.2 Level of uncertainty

The actual cost of settling insurance obligations may differ from the Best Estimate Liabilities because experience may be worse than assumed or future claims inflation may differ from that expected. There are a number of potential developments that would have a material adverse impact on the Best Estimate Liabilities value including:

- Catastrophic weather events;
- New types of latent claims;
- Unanticipated legislative changes;
- Unanticipated inflation.

Specific areas of uncertainty are:

- In conducting its insurance business, the Company receives general insurance liability claims, and becomes involved in actual or threatened related litigation arising therefrom, including claims in respect of pollution and other environmental hazards. Amongst these are claims in respect of asbestos production and handling. Given the significant delays that are experienced in the notification of these claims, the potential number of incidents which they cover and the uncertainties associated with establishing liability, the ultimate cost cannot be determined with certainty. Gross of reinsurance the level of uncertainty within the Technical Provisions for latent claims is high. The Company has extensive reinsurance in place against these claims so net of reinsurance the level of uncertainty is insignificant.
- PPO representing a material part of Best Estimate Liabilities. They also represent one of the most uncertain elements of the Company's Technical Provisions due to their long-tailed nature and the sensitivity to changes in economic-related assumptions. Additional uncertainty arises due to potential differences in the life expectancy of claimants compared to that expected, as well as the potential uncertainty in the propensity for non-life large injury claims to settle as PPO as opposed to lump sum awards. Gross of reinsurance the level of uncertainty within the Technical Provisions for PPO is very high. The Company purchases reinsurance to mitigate longevity risk in relation to these claims, which materially reduces the level of uncertainty.
- At present there is heightened uncertainty surrounding the cost of settlement for lump sum injury claims following recent developments in relation to the Ogden discount rate. On 27 February 2017, the Lord Chancellor announced a reduction in the discount rate used in the Ogden tables, which are used in the settlement of lump sum payments in bodily injury claims, from 2.5% set in 2001 to minus 0.75%. The valuation of the Company's SII Technical Provisions includes the impact of the reduction of the Ogden discount rate. The Lord Chancellor has also announced that the framework for setting the discount rate is under review. A public consultation was launched on 27 March 2017.

D.2.3 Material differences between the SII and IFRS valuation bases

The following table summarises gross of reinsurance SII technical provisions by material line of business and compares these to IFRS reclassified technical provisions. The information contained in this table is an extract from the SII Balance Sheet QRT S.02.01, presented in Appendix F.1.1.

Fechnical Provisions as at 31 December 2016 £m	Best Estimate Liability (BEL)	Risk Margin (unaudited) (RM)	SII Technical Provisions (BEL+RM)	IFRS reclassified Technical Provisions	Difference between SII and IFRS reclassified Technical Provisions
Total Non-life (excluding health)	5,624	135	5,759	6,496	(736)
- Motor vehicle liability	2,900	61	2,961	2,862	99
- Other motor insurance	165	4	169	210	(41)
- Fire and property damage	571	11	582	1,048	(466)
- General liability insurance	1,892	59	1,951	2,204	(253)
- Other Non-life	96	0	96	171	(75)
Health (similar to non-life)	80	4	84	134	(50)
Life (excluding health and index-linked and unit-linked)(PPO)	706	120	826	680	146
Total	6,410	259	6,669	7,309	(640)

On materiality grounds the Other Non-life row of this table groups together a number of the smaller non-life lines of business.

The material differences between the SII and IFRS valuation bases are summarised below:

- SII Technical Provisions include the Risk Margin (unaudited), which is not included within IFRS provisions, and which increases SII Technical Provisions compared to IFRS provisions.. This impacts on all lines of business, but has the greatest impact on the Life, Motor vehicle liability and General liability insurance lines of business;
- An explicit margin for uncertainty is included within IFRS provisions but removed under SII. This impacts all lines of business and reduces SII Technical Provisions compared to IFRS provisions;
- Only long-tailed claims reserves (predominantly latent claims within General liability insurance and PPO claims) are discounted within IFRS provisions, whereas all cash flows are discounted under SII. This difference reduces SII Technical Provisions compared to IFRS provisions and affects all lines of business, but with the most material impact on the Motor vehicle liability and General liability insurance lines of business given these classes typically contain longer duration cash flows which see relatively larger impacts from discounting under SII;
- The rate used to discount cash flows for PPO claims within IFRS provisions is higher than that used under SII. This increases SII Technical Provisions compared to IFRS provisions and impacts the Life line of business which contains the Company's PPO claims in payment, as well as the Motor vehicle liability and, to a lesser extent, General liability insurance lines of business which include provisions for claims which are expected to settle as PPO claims in the future;

- The rate used to discount cashflows for latent claims within IFRS provisions is lower than that used under SII, which reduces SII Technical Provisions compared to IFRS provisions. This impacts the General liability insurance line of business;
- The unearned premium reserve established under IFRS for all Non-life and Health lines of business is replaced with a Best Estimate premium provision which incorporates the expected cost of claims and expenses on the unearned periods of exposure. This typically leads to a lower premium provision under SII than the equivalent unearned premium reserves under IFRS. This difference impacts all Non-life and Health lines of business, but has proportionately larger impacts on the Fire and property damage and Other non-life lines of business;
- Under SII, provisions are established for Legally Obliged Unincepted Business, whereas these provisions are not included within the IFRS valuation basis. This difference impacts all Non-life and Health lines of business. This increases SII Technical Provisions compared to IFRS provisions.

D.2.4 Volatility Adjustment

The Volatility Adjustment removes temporary distortions in spreads caused by illiquidity in the market or extreme widening of credit spreads, in particular in relation to government bonds. The PRA has approved the Company's application to apply a Volatility Adjustment. The impact of the Volatility Adjustment is detailed in the Long Term Guarantees and Transitional measures QRT S.22.01. see Appendix F.1.5. The impact of removing the Volatility Adjustment from gross Technical Provisions would be to increase their value by £142m.

D.2.5 Other reliefs

No transitional provisions have been applied in the calculation of Technical Provisions

D.3 Other Liabilities

Other liabilities have been valued according to the requirements of the SII Directive and related guidance; the basis of the SII valuation principle is the amount for which they could be exchanged between knowledgeable willing parties in an arm's length transaction. A description of the basis of valuation under SII along with valuation differences between the SII bases and the IFRS financial statements, by material class, is provided below; if the valuation method has been described in the financial statements, or is an alternative method of valuation detailed in Section D.4, it has not been included in this section.

The Company's financial statements, provide information about contingent liabilities and other risk factors in note 26. The Company has no additional material contingent liabilities to recognise under SII.

D.3.1 Other Liabilities

Reinsurers' share of deferred acquisition costs of £270m and deferred income of £39m, included within other liabilities under IFRS, are not recognised and therefore valued at £nil in the SII balance sheet. Material differences in the valuation of Technical Provisions are explained in Section D.2.3. There are no other material differences between the IFRS and SII valuation bases.

D.3.2 Liabilities arising from leasing commitments

The future contractual aggregate minimum lease payment commitments under non-cancellable operating leases are £165m. . Further detail is provided in note 27 to the financial statements.

D.4 Alternative Methods of Valuation

The majority of the Company's assets and other liabilities are valued using quoted market information or observable market data. Maximum use has been made of market observable inputs when alternative methods of valuation have been adopted. The material assets and other liabilities, disclosed in the Balance Sheet QRT in Appendix F.1.1, that have alternative methods of valuation methods applied are as follows:

Participations

Participations of £1,211m are valued at the Company's proportionate equity share of the excess of assets over liabilities of each subsidiary, valued on a look through basis to the SII value of the assets and liabilities of the entity. This method is used because quoted prices from active markets in the equity of the subsidiaries are not available. The Company's investment in participations largely relates to its principal subsidiary ACI. Most of ACI's assets and liabilities are valued using quoted market information or observable market data. However, ACI values Defined Benefit Obligations, which are less than £90m, in accordance with the requirements of IAS19: Employee Benefits. The present value of future benefits is determined by projecting members' entitlements to the assumed retirement age. Expected payments are discounted to the valuation date reflecting future interest rates and mortality.

Property (other than own use)

Property (other than for own use) of £208m is recognised at its fair value as assessed by qualified external valuers using standard valuation practices. Values are calculated using a discounted cash flow approach and are based on current rental income plus anticipated uplifts at the next rent review, lease expiry, or break option taking into consideration lease incentives and assuming no growth in the estimated rental value of the property. This uplift and the discount rate are derived from rates implied by recent market transactions on similar properties. The valuation uncertainty of investment property has been assessed by reference to a range of estimated rental yields presented by a number of independent surveyors. This assessment indicates that the uncertainty relating to the valuation of property (other than own use) is immaterial.

Property funds

Collective investment undertakings include property funds of £127m. The underlying properties are valued based on external valuation reports received from fund managers. As with directly held property, the underlying properties are valued by third party surveyors using a discounted cash flow approach. An assessment of the valuation uncertainty of property funds, in line with the assessment of directly held property, indicated that the valuation uncertainty is immaterial.

Loans receivable

Loans receivable, of £2,087m under SII, principally comprise the Company's loans to its immediate parent AGH of £1,513m and the subordinated loans to its subsidiary ACI of CAD 350m and CAD 480m. The SII value of loans receivable includes accrued interest of £68m which is classified as accrued income under IFRS. These loans are valued using an income approach, which reflects the present value of contractual cash flows using discount rates calibrated as far as possible to relevant market observable parameters and taking into account any embedded features of the loan. In the absence of relevant market observable credit risk parameters, changes in credit risk are assessed according to any observable changes in the sufficiency of available collateral (including the surplus capital of the borrower) supporting the loans. The valuation uncertainty associated with loans receivable is considered to be immaterial.

Subordinated loan payable

The subordinated loan payable to AGH is valued at £290m (translated from CAD 480m at the year-end exchange rate) using an income approach which reflects the present value of contractual cash flows using discount rates calibrated as far as possible to relevant market observable parameters and taking into account any embedded features of the loan. In accordance with SII guidance, the discount rate is not adjusted for changes in credit risk of the borrower. The valuation uncertainty associated with the subordinated loan payable is immaterial.

Derivatives

Derivative assets and liabilities, with SII values of £130m and £228m respectively, are stated at fair value under IFRS and SII but include accrued income under SII. This is classified separately under IFRS. The majority of derivatives are over-the-counter derivatives and are valued by the broker based on an income approach using either discounted cash flow models or option pricing models and applying market observable inputs. The valuations are validated against counter-party statements. The valuation uncertainty associated with derivatives is immaterial.

D.5 Any Other Information

The Company has no other material information to disclose relating to the valuation of assets or liabilities.

Aviva Insurance Limited

Solvency and Financial Condition Report

2016

E. Capital Management

In this Chapter

- E.1 Own Funds
- E.2 Solvency Capital Requirement and Minimum Capital Requirement
- E.3 Use of Duration-Based Equity Risk Sub-Module in the Calculation of the Solvency Capital Requirement
- E.4 Differences between the Standard Formula and any Internal Model Used
- E.5 Non-Compliance with the Minimum Capital Requirement and Non-Compliance with the Solvency Capital Requirement
- E.6 Any Other Information

E. Capital Management

The 'Capital Management' section of the report describes the objectives, policies and procedures employed by the Company for managing its own funds. The section also covers information on structure and quality of Own Funds, calculation of SCR, including information about the Company's IM.

E.1 Own Funds

E.1.1 Management of Own Funds

The Company's policy on capital and risk management is set out in its Risk Management Framework. The Company's capital and risk management objectives are closely interlinked and support earnings growth and dividend policy, whilst also recognising the critical importance of protecting policyholder and other stakeholder interests. The Company's primary objective of managing capital efficiently is to optimise the balance between return and risk, whilst maintaining economic and regulatory capital surplus in accordance with approved risk appetites.

In managing its Own Funds the Company also seeks to:

- Match the profile of its assets and liabilities, taking account of the risks inherent in the business;
- Maintain sufficient, but not excessive, financial strength to support new business growth and satisfy the requirements of
 its policyholders and its regulator, the PRA;
- Retain financial flexibility by maintaining sufficient liquidity; and
- Allocate capital efficiently, applying it to support value adding growth and repatriating excess capital to its shareholder through dividends.

Own Funds are monitored via forecasts over a three year planning horizon. A number of stress and scenario tests are used to enable the Company to understand the volatility of its earnings and capital requirement, and therefore manage its capital more efficiently.

There have been no material changes to the objectives, policies or processes during the year.

E.1.2 Eligible Own Funds

An analysis of the Company's Own Funds by tier is presented in the Own Funds QRT S.23.01, (see Appendix F.1.6), and summarised below.

	Total	Tier 1 (unrestricted)	Tier 2	Tier 3
As at 31 December 2016	£m	£m	£m	£m
Ordinary share capital	204	204	-	-
Reconciliation reserve	2,024	2,024	-	-
Subordinated loan	290	-	290	-
An amount equal to net deferred tax assets	117	-	-	117
Total Basic Own Funds	2,635	2,228	290	117

Tiering analysis

The Company's ordinary share capital and reconciliation reserve are available to absorb losses and have the Tier 1 features of permanence and subordination. As the Company's Articles of Association do not contain any restriction on the right of the Company to cancel dividends or other distributions at any time before they are paid, the Company's ordinary share capital is classified as unrestricted Tier 1.

The Company's subordinated loan from AGH has the Tier 2 features of subordination and duration, as detailed below.

An amount equal to the value of net deferred tax assets is classified as Tier 3, as prescribed by the SII regulations.

Subordinated loan

In June 2016, the Company entered into a subordinated unsecured loan arrangement from AGH of CAD 480m. The loan accrues interest at 474 basis points above the Canadian Dealer Offered Rate and matures in 2046.

As at 31 December 2016, the loan has a carrying balance of £290m. There has been no material change in the valuation of the loan since it was issued in June 2016.

Reconciliation reserve

The Company's capital comprises ordinary share capital, capital reserves and retained earnings. Capital reserves and retained earnings are not separately disclosed in Own Funds. They are notionally included in the reconciliation reserve, which reconciles the total excess of assets over liabilities with identifiable capital instruments included in Own Funds.

The table below sets out the constituent parts of the reconciliation reserve as at 31 December 2016:

As at 31 December 2016	£m
SII excess of assets over liabilities	2,345
Ordinary share capital	(204)
An amount equal to net deferred tax assets	(117)
Reconciliation reserve	2,024

Eligibility of tiered Capital

The eligibility of tiered Capital, to cover the SCR and Minimum Capital Requirement (MCR) depends upon the tiering shown above and a number of quantitative limits. The Company's Own Funds satisfy all limits applicable to the SCR and therefore the eligibility of the Company's capital to cover the SCR is unrestricted. At least 80% of the MCR must be covered by Tier 1 capital and Tier 3 capital is not eligible to cover the MCR at all. As a result eligible funds to meet the MCR are restricted, as shown in the table below.

As at 31 December 2016	£m
Total eligible Own Funds to meet the SCR	2,635
Total eligible Own Funds to meet the MCR	2,291
The ratio of eligible Own Funds to the SCR and the MCR is detailed below.	
As at 31 December 2016	
Ratio of eligible Own Funds to the SCR	209%
Ratio of eligible Own Funds to the MCR	729%

E.1.3 Material differences between equity on an IFRS basis and Own Funds

At 31 December 2016, the Company's Own Funds of £2,635m are equal to the excess of assets over liabilities on a SII basis of £2,345m plus the subordinated loan of £290m.

The Company's excess of assets over liabilities on a SII basis was £1,949m less than its total equity on an IFRS basis. The following table details the material differences between the excess of assets over liabilities on a SII basis and total equity on an IFRS basis.

As at 31 December 2016	£m	£m	See Section
Total equity on an IFRS basis		4,294	
Elimination of goodwill and other intangible assets	(260)		D.1.1
Elimination of deferred acquisition costs	(532)		D.1.2
Valuation adjustments to investments in participations	(1,509)		D.1.4
Valuation adjustments to reinsurance recoverables	(567)		D.1.5
Valuation adjustments to Technical Provisions	640		D.2.3
Valuation adjustments to other liabilities	309		D.3.1
Net deferred tax adjustments	(30)		
		(1,949)	
Excess of assets over liabilities on a SII basis		2,345	

E.1.4 Transitional arrangements and restrictions

The Company's Own Funds are unrestricted and fully transferable.

E.2 Solvency Capital Requirement and Minimum Capital Requirement E.2.1 The amount of the SCR and MCR

The Company's SCR (unaudited) as at 31 December 2016 was £1.3bn. This is shown in the SCR QRT, S.25.02, see Appendix F.1.7

The Company's MCR as at 31 December 2016 was £0.3bn. This is shown on the MCR QRT, S.28.01, see Appendix F.1.8

The final amount of the SCR is subject to supervisory assessment and does not include any regulator-imposed capital add-ons.

E.2.2 The composition of the SCR (unaudited)

The Company determines its SCR using a PIM. The SCR of the IM component is £1.1bn and the SCR of the SF component £0.3bn. There is a diversification benefit of £0.1bn between the IM and SF results. Material risk categories for the IM component are shown below. The SF component predominantly relates to market risk associated with the ACI staff pension fund and the Company's non-insurance participations, which are treated as equity holdings within SF. Further detail is shown in the SCR QRT.

Diversified SCR by material risk category (per the SCR QRT) As at 31 December 2016	£b
Market risk	0.8
Non-life underwriting risk	0.6
Operational risk	0.4
Counterparty party risk	0.1
Other	0.2
Diversification between risk categories	(0.8)
Total SCR	1.3

Diversification benefits between risks are primarily driven by the relative size of risks and the correlations between them. For example, two risks diversify more if they are similarly sized and diversify less the more highly correlated they are. Diversification is also influenced by the shape of risk distributions, in that risks where extreme events are more likely tend to diversify better. The diversification benefit of £0.8bn in the table above is the diversification between the risk categories listed in the table. In addition, each risk category includes the impact of diversification within that risk. For example the non-life underwriting risk includes underwriting and reserve risk along with the diversification between them.

E 2.3 Simplifications, undertaking specific parameters and matching adjustment (unaudited)

Where the SCR is calculated using the SF, the SII regulations specify 23 simplified calculations that may be used across all of the SF risk modules risk modules except operational risk. The use of these simplifications is disclosed in QRT S.25.02 (Appendix F.1.7), where applicable. The Company has not used any of these simplified calculations to calculate the SCR at 31 December 2016.

Where the SCR is calculated using the SF, SII regulations specify certain undertaking specific parameters that may be used in place of the standard parameters, subject to regulatory approval. These are available for non-life (including some health) premium and reserve risks. The use of these undertaking specific parameters must be disclosed in QRT S.25.02 (Appendix F.1.7), where applicable. The Company has not used any undertaking specific parameters to calculate the SCR at 31 December 2016.

E.2.4 MCR Calculation

The Company's MCR is calculated by applying prescribed factors to its written premium and its net Best Estimate Liabilities. In accordance with the SII regulations premium and Best Estimate Liabilities of subsidiary companies are not included in the calculation. The MCR is subject to two further constraints; it must lie in the range of 25 to 45% of the Company's SCR and it cannot be less than an absolute minimum of £3.1m. The Company's MCR is currently 25% of its SCR.

E.3 Use of the duration-based eq	ity risk sub-module in the ca	alculation of the Solvency Capital
Requirement (unaudited)	•	

The Company does not use the duration-based equity risk sub-module in the calculation of the Company's SCR.

E.4 Differences between the Standard Formula and any Internal Model Used (unaudited)

E.4.1 Key uses of the IM

The IM provides input to a number of key business processes and activities. Therefore the outputs from the IM are used in day-to-day risk management and business decisions across the Company. "Use" does not imply that the IM is used to directly run the business, but rather that the outputs of the IM and the IM itself are used to support decision-making, whilst acknowledging its limitations and balancing against other elements of the Risk Management Framework.

The primary purpose of the Company's IM is to calculate the capital metrics, principally the SCR, required for regulatory reporting under SII. The outputs of the Company's IM are also used in risk-based performance reporting and risk and financial strength reporting to senior management, the Board, the shareholder and rating agencies.

The granular metrics produced by the IM are used in setting the Company's strategy and support a series of other activities including:

- Business planning, capital allocation, measurement of the risk-adjusted return and setting risk appetites;
- Improving pricing and product design by assessing the level of capital required to support different types of product;
- Assessing the appropriateness of potential acquisitions or business investments through the impact on surplus capital;
- Identifying the need for targeted reinsurance contracts to mitigate undesirable risk exposures, through modelling potential adverse scenarios; and
- Measuring the impact of market changes on assets and liabilities to drive investment strategy.

E.4.2 Scope of the IM and integration into the SF to derive the PIM

The Company uses a PIM to calculate its SCR. The IM component covers all of the Company's risk categories and takes into account the underlying risks of the Company's subsidiaries, subject to the exclusions detailed below.


The SCR is calculated using SF for the following elements of the Company's business:

- Private medical insurance business;
- ACI's staff pension fund;
- The Company's non insurance participations;
- The business associated with ACI's transaction with the Royal Bank of Canada, which is not yet included in the IM; and
- Household business underwritten by the Company's subsidiary, Gresham, to the extent it has not been reinsured to the Company.

The Company has chosen to use Integration Technique 2 within Method 2 as detailed in Annex XVIII of the Delegated Act, to combine the results of its IM and SF calculations. This technique requires specifying upper and lower bounds for correlations between the entire IM block and each of the SF risk modules. A correlation matrix is then constructed with correlations between these bounds such that it maximises the Basic SCR.

E.4.3 Method used in the IM for calculating the probability distribution forecast

The purpose of the IM is to identify the risks to which the Company is exposed, model these risks using suitably calibrated inputs and aggregate them to compute the SCR. An overview of the Company's approach is shown below.



The Company's IM allows flexibility in determining which statistical distributions to use to represent risk factors. This flexibility is important as it ensures that the behaviour of the most important risks to the Company is modelled appropriately.

For the market risk factors standard statistical distributions are used which are fitted via the standard risk factor calibration process. However, for other risk types, such as non-life underwriting and operational risk, distributions are derived from further modelling processes. This approach is appropriate given both the materiality of these risk types and the desire to ensure the risk's behaviour is adequately captured.

The Company uses a wide range of testing and review processes to ensure that the calibrations are appropriate and the IM outputs are reasonable. These range from bottom-up reviews of the material assumptions used in the modelling process and the testing of the calibrations and loss functions, to top-down stress and scenario testing, back testing and benchmarking.

Risk measure and time period used in the IM

The IM produces an aggregate distribution of the change in basic Own Funds over a one year time horizon from which the SCR can be directly derived, in line with Article 101. The SCR is the 99.5th percentile.

E.4.4 Material differences between the SF and IM methodologies and assumptions

The key difference between SF and the IM is that the IM has been tailored to the Company's risk profile. The IM calibrates a distribution of losses for each risk and uses these, together with a set of correlations between these risks, to derive a joint distribution of losses for the Company. The SCR is derived from this and ensures the Company holds sufficient capital to withstand a 1 in 200 year event. Calibrating risks for the IM therefore requires detailed data analysis and use of statistical models. SF simply uses prescribed formulae to calculate the capital required for each risk exposure.

Material differences between the SF and IM methodologies and assumptions by risk type are:

Market risk

- The Company's IM includes the risk on sovereign bonds, which is not included in SF.
- In the Company's IM interest rates are modelled in more detail to ensure changes in the slope and shape of the yield curve are captured. SF only considers the change in the level of interest rates.

Non Life underwriting risk

- Risks relating to latent claims and PPO are included in the IM using the Company's specific risk distributions. As SF does not explicitly address latent claims and PPO a company using SF would need to devise Undertaking Specific Parameters.
- Man made catastrophes are allowed for in the IM as an ENID, using Company specific parameters and taking into account diversification benefits. SF computes the impact of man made catastrophes formulaically.
- In SF the impact of inflation is implicitly captured in the calibration of the premium and reserve risks. The Company's IM separately identifies and calibrates RPI movements that can be traded.
- The Company's IM employs a finer level of granularity for material lines of business which allows for more distinction between material product types and in particular between commercial and personal lines which are grouped in SF.
- The Company's IM captures risks where the probability of extreme values is higher than normal, for example, PPO related to large personal injury claims. SF would not adequately capture the impact of these elements for the Company.

Operational risk

The Company's IM assesses operational risk using a scenario based approach. SF uses a simple formulaic approach.

Counterparty risk

- SF considers all counterparty default risk under one module. The Company's IM takes into account both the type of the counterparty and the nature of the exposure.
- The Company's IM considers default risk in more detail, taking into account spread risks and diversification between various credit exposures. SF does not consider these elements.

Aggregation, diversification and tax

- The Company's IM allows it to determine diversification at a more granular level and, capture important features such as its geographical diversification.
- The Company's IM uses explicit correlation matrices to combine sub-module losses within each risk module, and then to combine the calculated losses of the different risk modules. The SF uses a simpler hierarchical correlations approach.
- The Company's IM assesses loss functions net of tax. The SF calculation requires tax relief to be deducted from the gross SCR.

E.4.5 Data used in the IM

The data used in the Company's IM includes:

- Accounting data, computed on an IFRS basis, which is used in the valuation of assets and liabilities;
- Policy data from both policies in force and past policies that includes premium data, historic data on claims and exposure data potential catastrophic events such as on geographical concentrations;
- Operational risk data obtained from an external database covering industry operational risk losses, which is obtained from the Operational Risk Insurance Consortium;
- Financial market data, including asset data externally obtained such as from FTSE 100 index;
- Asset data including the market value of assets, most often derived from the accounting data;
- Other data including numerical, census or classification information, but excluding qualitative information.

As part of the Company's data governance process the appropriateness of the data is considered before it is used in the IM. Data accuracy, appropriateness and completeness are monitored on an ongoing basis by the Company's Data Governance Council. The data used in 2016 was formally approved on 15 February 2017.

E.5 Non-Compliance with the Minimum	Capital	Requirement	and Non-	Compliance	with the	Solvency
Capital Requirement		•		•		•

The Company has complied continuously with both the MCR and the SCR (unaudited) throughout the reporting period.

E.6 Any Other Information

The Company has no other material information to disclose.

Aviva Insurance Limited

Solvency and Financial Condition Report

2016

F. Appendices

In this Section

- .1	Public Disclosure Quantitative Reporting Templates
1.1	S.02.01 Balance Sheet
1.2.1	S.05.01 Premium claims and expenses (by line of business) [life]
1.2.2	S.05.01 Premium claims and expenses (by line of business) [non-life]
1.2.3	S.05.02 Premium claims and expenses (by country) [life]
1.2.4	S.05.02 Premium claims and expenses (by country) [non-life]
1.3.1	S.12.01 Technical Provisions [life]
1.3.2	S.17.01 Technical Provisions [non-life]
1.4	S.19.01 Insurance claims [non-life]
1.5	S.22.01 Impact of transitional measures
1.6	S.23.01 Own Funds
1.7	S.25.02 Solvency Capital Requirement
1.8	S.28.01 Minimum Capital Requirements
2	Glossary of Abbreviations and Definitions
=.3	Directors' Statement
- A	Auditors' Papart

		C0010
Assets		
Intangible assets	R0030	
Deferred tax assets	R0040	116,90
Pension benefit surplus	R0050	04.50
Property, plant & equipment held for own use	R0060	21,52
nvestments (other than assets held for index-linked and unit-linked contracts)	R0070	6,035,90
Property (other than for own use)	R0080 R0090	207,77
Holdings in related undertakings, including participations	R0100	1,211,04
Equities Listed	-	12,92
- Equities - Listed	R0110 R0120	10.00
- Equities - Unlisted Bonds	R0120	12,92 4,058,60
- Government Bonds	R0140	2,039,61
- Corporate Bonds	R0150	2,018,98
	R0160	2,010,90
- Structured Notes - Collateralised securities	R0170	
- Collateralised Securities Collective Investments Undertakings	R0170	404,08
Derivatives	R0190	129,83
	R0200	11,63
Deposits other than cash equivalents	- I	11,03
Other investments	R0210	
Assets held for index-linked and unit-linked contracts	R0220	0.007.04
Loans & mortgages	R0230	2,087,31
- Loans on policies	R0240	
- Loans & mortgages to individuals	R0250	0.007.01
- Other loans & mortgages	R0260	2,087,31
Reinsurance recoverables from:	R0270	4,524,70
- Reinsurance recoverables - Non-life and health similiar to non-life	R0280	3,902,18
- Reinsurance recoverables - Non-life excluding health	R0290	3,759,07
- Reinsurance recoverables - Health similar to non-life	R0300	143,11
- Reinsurance recoverables - Life and health similar to life, excluding health and index-linked and unit-linked	R0310	622,51
- Reinsurance recoverables - Health similar to life	R0320	
- Reinsurance recoverables - Life excluding health and index-linked and unit-linked	R0330	622,51
- Reinsurance recoverables - Life index-linked and unit-linked	R0340	
Deposits to cedants	R0350	
Insurance & intermediaries receivables	R0360	1,99
Reinsurance receivables	R0370	26,03
Receivables (trade, not insurance)	R0380	528,49
Own Shares (held directly)	R0390	
Amounts due in respect of own fund items or initial fund called up but not yet paid in	R0400	
Cash and cash equivalents	R0410	341,37
Any other assets, not elsewhere shown	R0420	54,97
Total assets	R0500	13,739,223
Liabilities		
Technical provisions - Non-life	R0510	5,842,71
- Technical provisions - Non-life (excluding health)	R0520	5,759,42
- TP calculated as a whole - Non-life (excluding health)	R0530	
- Best Estimate - Non-life (excluding health)	R0540	5,624,33
- Risk margin - Non-life (excluding health)	R0550	135,09
- Technical provisions - Health (similar to non-life)	R0560	83,28
	R0570	
- TP calculated as a whole - Health (similar to non-life)	_	79,68
- TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life)	R0580	3,599
- Best Estimate - Health (similar to non-life)	R0580 R0590	
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life)	R0580 R0590 R0600	
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked)	R0590 R0600	
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life)	R0590 R0600 R0610	
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life)	R0590 R0600 R0610 R0620	
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-ninked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life)	R0590 R0600 R0610 R0620 R0630	
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life)	R0590 R0600 R0610 R0620 R0630 R0640	826,16
Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) Technical provisions - Health (similar to life) Best Estimate - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked)	R0590 R0600 R0610 R0620 R0630 R0640 R0650	826,16
Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) Technical provisions - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) Technical provisions - Life (excluding health, index-linked and unit-linked)	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660	826,16: 826,16:
Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) Technical provisions - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) Technical provisions - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked)	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670	826,16: 826,16: 706,27:
Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) Te calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) Te calculated as a whole - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked)	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680	826,16: 826,16: 706,27:
Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) Technical provisions - Health (similar to life) Best Estimate - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) Technical provisions - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked)	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690	826,16: 826,16: 706,27:
Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) Technical provisions - Index-linked and unit-linked) - TP calculated as a whole - Index-linked and unit-linked	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690 R0700	826,16: 826,16: 706,27:
Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Technical provisions - Index-linked and unit-linked and unit-linked) - TP calculated as a whole - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690 R0700 R0710	826,16: 826,16: 706,27:
Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - Te calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) Technical provisions - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690 R0700 R0710 R0720	826,16: 826,16: 706,27:
Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - Te calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - Te calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Technical provisions - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690 R0700 R0710 R0720 R0740	826,16 826,16 706,27 119,88
Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) Technical provisions - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked	R0590 R0600 R0610 R0610 R0630 R0640 R0650 R0660 R0670 R0680 R0700 R0710 R0720 R0740 R0750	826,16: 826,16: 706,27: 119,88:
Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - The calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excling health and index-linked and unit-linked) - The calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) Technical provisions - Index-linked and unit-linked - The calculated as a whole - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked Contingent liabilities Provisions other than technical provisions Pension benefit obligations	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0700 R0710 R0720 R0740 R0750 R0750 R0760	826,16: 826,16: 706,27: 119,88: 27,94:
Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - TP calculated as a whole - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Risk margin - Index-linked son unit-linked - Risk margin - Index-linked son unit-linked - Risk margin - Index-linked son unit-linked	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0700 R0710 R0720 R0740 R0750 R0760 R0770	826,16 826,16 706,27 119,88 27,94
Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) Technical provisions - Index-linked and unit-linked - Pest Estimate - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0700 R0710 R0720 R0740 R0750 R0770 R0770	826,16 826,16 706,27 119,88 27,94 2,958,07 17,90
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - TP calculated as a whole - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked Contingent liabilities Provisions other than technical provisions Pension benefit obligations Deposits from reinsurers Deferred tax liabilities Derivatives	R0590 R0600 R0610 R0610 R0630 R0640 R0650 R0660 R0670 R0690 R0700 R0700 R0720 R0740 R0750 R0760 R0770 R0770 R0780 R0790	826,16 826,16 706,27 119,88 27,94 2,958,07 17,90 227,81
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Risk margin - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0700 R0710 R0720 R0740 R0750 R0760 R0770 R0770 R0770 R0770 R0780 R0790 R0790 R0800	826,16 826,16 706,27 119,88 27,94 2,958,07 17,90 227,81 409,71
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - TP calculated as a whole - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0710 R0720 R0740 R0750 R0770 R0780 R0780 R0780 R0800 R0800 R0810	826,16 826,16 706,27 119,88 27,94 2,958,07 17,90 227,81 409,71 32,86
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - TP calculated as a whole - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0650 R0690 R0700 R0710 R0720 R0740 R0750 R0770 R0780 R0790 R0790 R0801 R0790 R0810 R0810 R0820	826,16 826,16 706,27 119,88 27,94 2,958,07 17,90 227,81 409,71 32,86 70,99
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - TP calculated as a whole - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0710 R0720 R0740 R0750 R0770 R0780 R0780 R0780 R0800 R0800 R0810	826,16 826,16 706,27 119,88 27,94 2,958,07 17,90 227,81 409,71 32,86 70,99
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - TP calculated as a whole - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked Contingent liabilities Provisions other than technical provisions Pension benefit obligations Deposits from reinsurers Detposits from reinsur	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0650 R0690 R0700 R0710 R0720 R0740 R0750 R0770 R0780 R0790 R0790 R0801 R0790 R0810 R0810 R0820	826,16 826,16 706,27 119,88 27,94 2,958,07 17,90 227,81 409,71 32,86 70,99 16,89
Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Technical provisions - Index-linked and unit-linked and unit-linked) - TP calculated as a whole - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked	R0590 R0600 R0610 R0610 R0630 R0640 R0650 R0660 R0670 R0680 R0700 R0700 R0740 R0750 R0760 R0770 R0780 R0790 R0790 R0800 R0800 R0800 R0820 R0820	27,94 2,958,07 17,90 227,81 409,71 32,86 70,99 16,89 285,81 289,66
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Risk margin - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked - Desposits from reinsurers - Deferred tax liabilities other than debts owed to credit institutions	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0710 R0720 R0710 R0720 R0740 R0750 R0760 R0770 R0780 R0790 R0810 R0800 R0810 R0800 R0810 R0830 R0830 R0830	826,16 826,16 706,27 119,88 27,94 2,958,07 17,90 227,81 409,71 32,86 70,99 16,89 285,81
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Risk margin - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked - Provisions other than technical provisions - Pension benefit obligations - Deposits from reinsurers - Deferred tax liabilities - Derivatives - Deferred tax liabilities - Derivatives - Deterred tax liabilities - Derivatives - Risk margin - Index-linked institutions - Risk margin	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0660 R0670 R0700 R0710 R0720 R0740 R0750 R0760 R0770 R0780 R0790 R0800 R0810 R0820 R0820 R0820 R0820 R0820 R0820 R0820 R0830	826,16: 826,16: 706,27: 119,88: 27,94: 2,958,07: 17,90: 227,81: 409,71: 32,86: 70,99: 16,89: 285,81:
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - TP calculated as a whole - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Best Estimate - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked - Provisions other than technical provisions - Pension benefit obligations - Deposits from reinsurers - Deferred tax liabilities - Derivatives - Debts owed to credit institutions - Insurance & intermediaries payables - Reinsurance payables - Reinsurance payables - Reyables (trade, not insurance) - Subordinated liabilities - Subordinated liabilities	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0660 R0670 R0710 R0720 R0740 R0750 R0760 R0770 R0780 R0790 R0800	826,16 826,16 706,27 119,88 27,94 2,958,07 17,90 227,81 409,71 32,86 70,99 16,89 285,81 289,66
- Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked) - TP calculated as a whole - Life (excl health, index-linked and unit-linked) - Best Estimate - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - Risk margin - Life (excl health, index-linked and unit-linked) - TP calculated as a whole - Index-linked and unit-linked - TP calculated as a whole - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked - Risk margin - Index-linked and unit-linked Contingent liabilities Provisions other than technical provisions Pension benefit obligations Deposits from reinsurers Deferred tax liabilities Derivatives Debts owed to credit institutions Financial liabilities other than debts owed to credit institutions Insurance & intermediaries payables Reinsurance payables Payables (trade, not insurance) Subordinated liabilities on in BOF - Subordinated liabilities in BOF	R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0700 R0710 R0720 R0740 R0750 R0770 R0780 R0790 R0800 R0810 R0820 R0830 R0840 R0840 R0860 R0870	826,16 826,16 706,27 119,88 27,94 2,958,07 17,90 227,81 409,71 32,86 70,99 16,89 285,81 289,66

Appendix F.1.2.1 S.05.01.02

Premiums, claims and expenses by line of business

Amounts in 000s

				ine of Business for: li	fe insurance obligation	s		Life reinsurar	ce obligations	
		Health Insurance (direct business)	Insurance with profit participation	Index-linked and unit-linked insurance	Other life insurance	Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Annuities stemming from non-life insurance contracts and relating to insurance obligations other than health insurance	Health reinsurance (reinsurance accepted)	Life reinsurance	Total
		C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0300
Premiums written										
Gross - Direct Business	R1410									
Reinsurers' share	R1420									
Net	R1500									
Premiums earned										
Gross - Direct Business	R1510									
Reinsurers' share	R1520									
Net	R1600									
Claims incurred										
Gross - Direct Business	R1610						212,631			212,631
Reinsurers' share	R1620						164,404			164,404
Net	R1700						48,227			48,227
Changes in other technical provisions										
Gross - Direct Business	R1710									
Reinsurers' share	R1720									
Net	R1800									
Expenses incurred	R1900									
Other expenses	R2500									
Total expenses	R2600									

Premiums, claims and expenses by line of business

Amounts in 000s

			Line of Business for: non-life insurance Income protection Income prot										
		Medical expense insurance		compensation				damage to property		suretyship	Legal expenses insurance	Assistance	Miscellaneous financial loss
		C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120
Premiums written													
Gross - Direct Business	R0110	564,479	98,898		1,489,174	377,721	15,318	1,982,478	399,562	28,215		34,248	70,895
Gross - Proportional reinsurance accepted	R0120						16,995	18,779	2,370	1,248			
Gross - Non-proportional reinsurance accepted	R0130												
Reinsurers' share	R0140	404,714	89,353		2,073,345	518,687	53,901	1,628,988	836,323			22,425	67,070
Net	R0200	159,765	9,545		-584,171	-140,966	-21,589	372,270	-434,392	3,827		11,823	3,825
Premiums earned													
Gross - Direct Business	R0210	562,637	96,293		1,472,857	374,195	15,776	1,856,036	391,799	26,602		34,187	75,613
Gross - Proportional reinsurance accepted	R0220						16,995	19,026	2,216	1,248			
Gross - Non-proportional reinsurance accepted	R0230												
Reinsurers' share	R0240	299,755	77,466		1,745,122	436,667	46,856	1,226,675	746,589	18,938		20,681	63,132
Net	R0300	262,882	18,827		-272,265	-62,472	-14,085	648,386	-352,574	8,913		13,506	12,481
Claims incurred													
Gross - Direct Business	R0310	416,502	40,235		1,485,252	329,549	15,523	766,225	424,007	15,159		24,037	29,116
Gross - Proportional reinsurance accepted	R0320						10,904	8,649	1,155	584			
Gross - Non-proportional reinsurance accepted	R0330												
Reinsurers' share	R0340	223,835	34,001		1,609,115	390,673	28,473	652,924	763,749	15,199		15,304	31,995
Net	R0400	192,667	6,234		-123,863	-61,124	-2,046	121,950	-338,586	543		8,733	-2,879
Changes in other technical provisions													
Gross - Direct Business	R0410		535										535
Gross - Proportional reinsurance accepted	R0420												
Gross - Non-proportional reinsurance accepted	R0430												
Reinsurers' share	R0440		3,155										3,155
Net	R0500		-2,620										-2,620
Expenses incurred	R0550	58,955	21,934		211,939	54,544	-4,592	517,714	73,998	6,677		5,189	25,724
Other expenses	R1200												
Total expenses	R1300												

		Line of	Business for: accepte	ed non proportional reins	surance	
		Non-proportional health reinsurance	Non-proportional casualty reinsurance	Non-proportional marine, aviation and transport reinsurance	Non-proportional property reinsurance	Total
		C0130	C0140	C0150	C0160	C0200
Premiums written						
Gross - Direct Business	R0110					5,060,987
Gross - Proportional reinsurance accepted	R0120					39,392
Gross - Non-proportional reinsurance accepted	R0130					
Reinsurers' share	R0140					5,720,442
Net	R0200					-620,063
Premiums earned						
Gross - Direct Business	R0210					4,905,995
Gross - Proportional reinsurance accepted	R0220					39,485
Gross - Non-proportional reinsurance accepted	R0230					
Reinsurers' share	R0240					4,681,881
Net	R0300					263,599
Claims incurred						
Gross - Direct Business	R0310					3,545,606
Gross - Proportional reinsurance accepted	R0320					21,292
Gross - Non-proportional reinsurance accepted	R0330					
Reinsurers' share	R0340					3,765,267
Net	R0400					-198,370
Changes in other technical provisions						
Gross - Direct Business	R0410					1,069
Gross - Proportional reinsurance accepted	R0420					
Gross - Non-proportional reinsurance accepted	R0430					
Reinsurers' share	R0440					6,309
Net	R0500					-5,240
Expenses incurred	R0550					972,082
Other expenses	R1200					75,237
Total expenses	R1300					1,047,319

Appendix F.1.2.3 S.05.02.01

Premiums, claims and expenses by Country

Amounto in 000c

Amounts in 000s								
		Home Country		Top 5 countries (by a	mount of gross premiu	s written) - life obligation	าร	Total Top 5 and home country
	'	C0150	C0160	C0170	C0180	C0190	C0200	C0210
	R1400							
		C0220	C0230	C0240	C0250	C0260	C0270	C0280
Premiums written								
Gross	R1410							0
Reinsurers' share	R1420							0
Net	R1500							0
Premiums earned								
Gross	R1510							0
Reinsurers' share	R1520							0
Net	R1600							0
Claims incurred								
Gross	R1610	212,631						212,631
Reinsurers' share	R1620	164,404						164,404
Net	R1700	48,227						48,227
Changes in other technical provisions								
Gross	R1710							0
Reinsurers' share	R1720							0
Net	R1800							0
Expenses incurred	R1900							0
Other expenses	R2500					1		
Total expenses	R2600							0

Appendix F.1.2.4 S.05.02.01 Premiums, claims and expenses by Country Amounts in 000s

		Home Country	Тор	5 countries (by amount	of gross premium writi	ten) - non-life obligation	s	Total Top 5 and home country
		C0010	C0020	C0030	C0040	C0050	C0060	C0070
	R0010		IE	ES	NL	AE	DE	
		C0080	C0090	C0100	C0110	C0120	C0130	C0080
Premiums written								
Gross - Direct Business	R0110	4,567,505	399,922	22,341	17,518	11,178	10,617	5,029,081
Gross - Proportional reinsurance accepted	R0120	36,510	397		294			37,200
Gross - Non-proportional reinsurance accepted	R0130							0
Reinsurers' share	R0140	5,106,658	574,673	11,035	9,581	1	6,347	5,708,294
Net	R0200	-502,644	-174,355	11,306	8,231	11,178	4,271	-642,013
Premiums earned								
Gross - Direct Business	R0210	4,441,794	372,478	22,305	17,544	10,210	10,705	4,875,036
Gross - Proportional reinsurance accepted	R0220	36,602	397		294			37,293
Gross - Non-proportional reinsurance accepted	R0230							0
Reinsurers' share	R0240	4,160,332	482,290	11,045	9,598	1	6,406	4,669,672
Net	R0300	318,064	-109,415	11,260	8,239	10,209	4,299	242,656
Claims incurred								
Gross - Direct Business	R0310	3,182,647	195,944	7,092	6,340	10,914	102,454	3,505,391
Gross - Proportional reinsurance accepted	R0320	21,151	90		11			21,252
Gross - Non-proportional reinsurance accepted	R0330							0
Reinsurers' share	R0340	3,276,665	373,029	3,498	3,475	0	91,339	3,748,006
Net	R0400	-72,866	-176,995	3,594	2,876	10,913	11,115	-221,363
Changes in other technical provisions								
Gross - Direct Business	R0410	1,069						1,069
Gross - Proportional reinsurance accepted	R0420							0
Gross - Non-proportional reinsurance accepted	R0430							0
Reinsurers' share	R0440	6,309						6,309
Net	R0500	-5,240						-5,240
Expenses incurred	R0550	877,163	68,837	7,064	4,808	2,967	2,261	963,099
Other expenses	R1200							75,237
Total expenses	R1300							1,038,335

Appendix F.1.3.1 S.12.01.02

Life and Health SLT Technical Provisions

Amounts in 000s

		Insurance with profit participation		Index-linked and unit-linked insurance			Other life insurance		Annuities stemming from non-life insurance contracts and relating to insurance obligations other	Accepted Reinsurance	
				Contracts without options and quarantees	Contracts with options or quarantees		Contracts without options and quarantees	Contracts with options or quarantees			Total (Life other than health insurance, incl. Unit
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0150
Technical provisions calculated as a whole	R0010										
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole Technical provisions calculated as a sum of BE and RM	R0020										
Best Estimate											
Gross Best Estimate	R0030								705,359	920	706,279
Total Recoverables from reinsurance and SPV after the adjustment for expected losses due to counterparty default	R0080								622,516		622,516
Best estimate minus recoverables from reinsurance and SPV - Total	R0090								82,843	920	83,763
Risk Margin	R0100								119,883		119,883
Amount of the transitional on Technical Provisions											
Technical Provisions calculated as a whole	R0110										
Best estimate	R0120										
Risk margin	R0130										
Technical provisions - Total	R0200								825,241	920	826,162

			Health Insurance (direct business)		Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Health reinsurance (reinsurance accepted)	
			Contracts without options and quarantees	Contracts with options or quarantees			Total (Health similar to life insurance)
		C0160	C0170	C0180	C0190	C0200	C0210
Technical provisions calculated as a whole	R0010						
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole	R0020						
Technical provisions calculated as a sum of BE and RM							
Best Estimate							
Gross Best Estimate	R0030						
Total Recoverables from reinsurance and SPV after the adjustment for expected losses due to counterparty default	R0080						
Best estimate minus recoverables from reinsurance and SPV - Total	R0090						
Risk Margin	R0100						
Amount of the transitional on Technical Provisions							
Technical Provisions calculated as a whole	R0110						
Best estimate	R0120						
Risk margin	R0130						
Technical provisions - Total	R0200						

						Direct business	and accepted	proportional	reinsurance				
		Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance	Legal expenses insurance	Assistance	Miscellaneous financial loss
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130
Technical provisions calculated as a whole	R0010												
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for	R0050												
expected losses due to counterparty default associated to TP as a whole Technical provisions calculated as a sum of BE and RM													
Best estimate													
Premium provisions													
Gross	R0060	26,706	-27,572		272,215	80,887	3,964	89.896	39.604	3,762		7,707	-17,770
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for							-	,					-
expected losses due to counterparty default	R0140	92,613	9,183		280,900	97,267	4,246	209,596	61,523	5,219		8,692	15,038
Net Best Estimate of Premium Provisions	R0150	-65,906	-36,755		-8,685	-16,380	-281	-119,700	-21,919	-1,457		-985	-32,808
Claims provisions													
Gross	R0160	49,345	31,208		2,627,266	84,275	50,790	481,085	1,852,617	22,334		10,509	14,394
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0240	24,679	16,638		1,323,670	47,429	35,936	292,552	1,349,304	13,909		5,722	7,667
Net Best Estimate of Claims Provisions	R0250	24,667	14,570		1,303,596	36,845	14,854	188,533	503,313	8,424		4,787	6,726
Total Best estimate - Gross	R0260	76,052	3,636		2,899,481	165,162	54,755	570,981	1,892,221	26,096		18,216	-3,376
Total Best estimate - Net	R0270	-41,240	-22,184		1,294,911	20,465	14,573	68,833	481,394	6,968		3,802	-26,082
Risk margin	R0280	3,308	292		60,580	3,621	174	11,271	58,871	128		218	226
Amount of the transitional on Technical Provisions													
Technical Provisions calculated as a whole	R0290												
Best estimate	R0300												
Risk margin	R0310												
Technical provisions - Total													
Technical provisions - Total	R0320	79,359	3,928		2,960,061	168,783	54,928	582,252	1,951,092	26,224		18,434	-3,150
Recoverable from reinsurance contract/SPV and Finite Re after the adjustment for expected losses due to counterparty default - Total	R0330	117,292	25,821		1,604,570	144,697	40,182	502,148	1,410,827	19,128		14,415	22,705
Technical provisions minus recoverables from reinsurance/SPV and Finite Re- Total	R0340	-37,932	-21,893		1,355,491	24,086	14,746	80,104	540,265	7,096		4,020	-25,856

		Accepted	non-proportional	reinsurance		
		Non-proportional health reinsurance	Non-proportional casualty reinsurance	Non-proportional marine, aviation and transport reinsurance	Non-proportional property reinsurance	Total Non-Life obligation
		C0140	C0150	C0160	C0170	C0180
Technical provisions calculated as a whole	R0010					
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole	R0050					
Technical provisions calculated as a sum of BE and RM						
Best estimate						
Premium provisions						
Gross	R0060					479,401
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0140					784,277
Net Best Estimate of Premium Provisions	R0150					-304,877
Claims provisions						
Gross	R0160		798	3		5,224,624
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0240		399	2		3,117,908
Net Best Estimate of Claims Provisions	R0250		399	2		2,106,716
Total Best estimate - Gross	R0260		798	3		5,704,024
Total Best estimate - Net	R0270		399	2		1,801,839
Risk margin	R0280					138,689
Amount of the transitional on Technical Provisions						
Technical Provisions calculated as a whole	R0290					
Best estimate	R0300					
Risk margin	R0310					
Technical provisions - Total						
Technical provisions - Total	R0320		798	3		5,842,714
Recoverable from reinsurance contract/SPV and Finite Re after the adjustment for expected losses due to counterparty default - Total	R0330		399	2		3,902,185
Technical provisions minus recoverables from reinsurance/SPV and Finite Re - Total	R0340		399	2		1,940,528

Appendix F.1.4 S.19.01.21

Non-Life Insurance Claims Information Amounts in 000s

Total Non-Life Business

Accident year / Underwriting year	Z0010	AY

Gross Claims Paid (non-cumulative)

(absolute amount)

						Development Y	ear							In Current year	Sum of years (cumulative)
		0	1	2	3	4	5	6	7	8	9	10&+			
		C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110		C0170	C0180
Prior	R0100											72,337	R0100	72,337	16,415,369
N-9	R0160	2,244,137	1,281,810	337,081	211,414	192,418	124,910	55,901	31,182	14,796	9,920		R0160	9,920	4,503,568
N-8	R0170	1,962,617	979,156	273,997	245,380	176,938	106,973	57,919	31,521	10,840			R0170	10,840	3,845,342
N-7	R0180	1,665,660	838,393	299,084	173,944	144,262	76,165	45,390	19,799				R0180	19,799	3,262,698
N-6	R0190	1,374,682	896,851	244,270	179,792	122,844	83,767	40,602					R0190	40,602	2,942,808
N-5	R0200	1,321,374	691,267	242,308	167,360	152,396	78,254						R0200	78,254	2,652,960
N-4	R0210	1,463,565	701,528	262,209	192,060	148,315							R0210	148,315	2,767,677
N-3	R0220	1,412,067	642,195	227,948	160,865								R0220	160,865	2,443,075
N-2	R0230	1,436,889	614,197	216,330									R0230	216,330	2,267,416
N-1	R0240	1,459,289	736,632										R0240	736,632	2,195,921
N	R0250	1,520,151											R0250	1,520,151	1,520,151
												T-	otal R0260	3,014,044	44,816,986

Gross undiscounted Best Estimate Claims Provisions

(absolute amount)														
						Development	Year							Year end (discounted data)
		0	1	2	3	4	5	6	7	8	9	10&+		(alboounica aata)
		C0200	C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0290	C0300		C0360
Prior	R0100											1,264,731	R0100	1,043,451
N-9	R0160										19,871		R0160	22,449
N-8	R0170									42,096			R0170	40,932
N-7	R0180								12,908				R0180	11,702
N-6	R0190							81,339					R0190	79,825
N-5	R0200						155,431						R0200	152,602
N-4	R0210					326,977							R0210	320,663
N-3	R0220				463,877								R0220	455,219
N-2	R0230			630,619									R0230	618,887
N-1	R0240		966,499										R0240	948,076
N	R0250	1,556,046											R0250	1,530,817
												1	Total R0260	5,224,624

Appendix F.1.5

S.22.01.21

Impact of long term guarantees and transitional measures

Amounts in 000s

	m 1
Technical Provisions R0010	
Basic Own Funds R0020	
Eligible own funds to meet Solvency Capital Requirement R0050	
Solvency Capital Requirement R0090	
Eligible own funds to meet Minimum Capital Requirement R0100	
Minimum Capital Requirement R0110	

Amount with LG measures and transitionals	Impact of transitional on technical provisions	Impact of transitional on interest rate	Impact of volatility adjustment set to zero	Impact of matching adjustment set to zero
C0010	C0030	C0050	C0070	C0090
6,668,875			141,528	0
2,635,076			-30,019	0
2,635,076	0	0	-30,019	0
1,257,923			53,200	
2,291,405	0	0	-27,359	0
314 481			13 300	

		Total	Tier 1 Unrestricted	Tier 1 Restricted	Tier 2	Tier 3
		C0010	C0020	C0030	C0040	C0050
Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation 2015/35						
Ordinary share capital (gross of own shares)	R0010	203,640	203,640			
Share premium account related to ordinary share capital	R0030					
Total initial funds, members' contributions or the equivalent basic own - fund item for mutual and mutual type undertakings	R0040					
Subordinated mutual member accounts	R0050	0		0		
Surplus funds	R0070	-				
Preference shares	R0090					
Share premium account related to preference shares	R0110					
Reconciliation reserve	R0130	2,024,869	2,024,869			
Subordinated liabilities	R0140	289,663			289,663	
An amount equal to the value of net deferred tax assets	R0160	116,904				116,904
Own fund from financial statements do not meet the criteria to be classified as	R0180					
Solvency II own funds Own funds from the financial statements that should not be represented by the reconcilitation reserve and do not meet the criteria to be classified as Solvency						
Il own funds Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II	R0220					
own funds Deductions						
Deductions for participations in financial and credit institutions	R0230					
Total basic own funds after deductions	R0290	2,635,076	2,228,509	0	289,663	116,904
Ancillary own funds						
Unpaid and uncalled ordinary share capital callable on demand	R0300					
Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual - type undertakings, callable on demand	R0310					
Unpaid and uncalled preference shares callable on demand	R0320					
A legally binding commitment to subscribe and pay for subordinated liabilities on	R0330					
demand Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC	R0340					
Letters of credit and guarantees under Anticle 96(2) of the Directive						
2009/138/EC	R0350					
Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC Supplementary members calls - Other than under first subparagraph of Article 96(3)	R0360					
of the Directive 2009/138/EC	R0370					
Other ancillary own funds	R0390					
Total ancillary own funds	R0400					
Available and eligible own funds				L		
Total available own funds to meet the SCR	R0500	2,635,076	2,228,509	0	289,663	116,904
Total available own funds to meet the MCR	R0510	2,518,171	2,228,509	0	289,663	-,
Total eligible own funds to meet the SCR	R0540	2,635,076	2,228,509	0	289,663	116,904
Total eligible own funds to meet the MCR	R0550	2,291,405	2,228,509	0	62,896	
SCR	R0580	1,257,923				
MCR	R0600	314,481				
Ratio of Eligible own funds to SCR	R0620	2.0948				
Ratio of Eligible own funds to MCR	R0640	7.2863				
		C0060				
Reconciliation Reserve	D0700	0.045.440				
Excess of assets over liabilities Own shares (direct/indirect)	R0700 R0710	2,345,413				
Foreseeable dividends, distributions and charges	R0710					
Other basic own fund items	R0730	320,544				
Adjustment for restricted own fund items in respect of matching adjustment		320,544				
portfolios and ring fenced funds	R0740					
Reconciliation reserve	R0760	2,024,869			,	
Expected profits						
	R0770					
Expected profits included in future premiums (EPIFP) - Life business						
Expected profits included in future premiums (EPIFP) - Life business Expected profits included in future premiums (EPIFP) - Non-life business Total Expected profits included in future premiums (EPIFP)	R0780 R0790	2,392 2,392				

Appendix F.1.7

S.25.02.21

Solvency Capital Requirement - For undertakings using the standard formula and partial internal mod

Amounts in 000s

Unique number of component	Component Description
C0010	C0020
100000	Market Risk
200000	Counterparty Risk
300000	Life underwriting risk
400000	Health underwriting risk
500000	Non-life underwriting risk
701000	Operational risk
801000	Other risks
802000	Loss-absorbing capacity of technical provisions
803000	Loss-absorbing capacity of deferred tax
804000	Other adjustments

Calculation of the Solvency Capital Requirement	Amount modelled	USP	Simplifications
C0030	C0070	C0080	C0090
784,729	525,281		
144,985	134,138		
40,940			
594,031	594,031		
404,130	388,762		
-92,727	-92,727		
136,599	136,599		

Calculation of Solvency Capital Requirement		C0100
Total undiversified components	R0110	2,012,686
Diversification	R0060	-754,763
Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC	R0160	
Solvency Capital Requirement excluding capital add-on	R0200	1,257,923
Capital add-ons already set	R0210	
Solvency capital requirement	R0220	1,257,923
Other information on SCR		
Amount/Estimate of the overall loss-absorbing capacity of technical provisions	R0300	
Amount/Estimate of the overall loss-absorbing capacity of deferred taxes	R0310	-92,727
Capital requirement for duration-based equity risk sub-module	R0400	
Total amount of Notional Solvency Capital Requirements for remaining part	R0410	
Total amount of Notional Solvency Capital Requirements for ring fenced funds (other than those related to business operated in accordance with Art. 4 of Directive 2003/41/EC (transitional))	R0420	
Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios	R0430	
Diversification effects due to RFF nSCR aggregation for article 304	R0440	

Appendix 1.8 S.28.01.01

Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

Amounts in 000s

Linear formula component for non-life insurance and reinsurance obligations

		C0010	
MCRNL Result	R0010	209,317	

		Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months
		C0020	C0030
Medical expense insurance and proportional reinsurance	R0020		159,765
Income protection insurance and proportional reinsurance	R0030		9,545
Workers' compensation insurance and proportional reinsurance	R0040		
Motor vehicle liability insurance and proportional reinsurance	R0050	1,294,911	
Other motor insurance and proportional reinsurance	R0060	20,465	
Marine, aviation and transport insurance and proportional reinsurance	R0070	14,573	
Fire and other damage to property insurance and proportional reinsurance	R0080	68,833	372,270
General liability insurance and proportional reinsurance	R0090	481,394	
Credit and suretyship insurance and proportional reinsurance	R0100	6,968	3,827
Legal expenses insurance and proportional reinsurance	R0110		
Assistance and proportional reinsurance	R0120	3,802	11,823
Miscellaneous financial loss insurance and proportional reinsurance	R0130		3,825
Non-proportional health reinsurance	R0140		
Non-proportional casualty reinsurance	R0150	399	
Non-proportional marine, aviation and transport reinsurance	R0160	2	
Non-proportional property reinsurance	R0170		

Linear formula component for life insurance and reinsurance obligations

C0040 MCRL Result R0200

		Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk
		C0050	C0060
Obligations with profit participation - Guaranteed benefits	R0210		
Obligations with profit participation - Future discretionary benefits	R0220		
Index-linked and unit-linked insurance obligations	R0230		
Other life (re)insurance and health (re)insurance obligations	R0240	83,763	
Total capital at risk for all life (re)insurance obligations	R0250		

Overall MCR calculation

		C0070
Linear MCR	R0300	211,076
SCR	R0310	1,257,923
MCR cap	R0320	566,065
MCR floor	R0330	314,481
Combined MCR	R0340	314,481
Absolute floor of the MCR	R0350	3,332
		C0070
Minimum Capital Requirement	R0400	314,481

F.2 Glossary of Abbreviations and Definitions

99.5% percentile An event that would be expected to occur once in every 200 years

ACI Aviva Canada Inc.

AGH Aviva Group Holdings Limited

All Aviva Insurance Limited, the Company
AllL Aviva International Insurance Limited

ALCO Asset and Liability Committee

Alternative

Valuation methods that are consistent with Article 75 of the SII Directive other than those which solely use the

valuation methods quoted market prices for the same or similar assets or liabilities"

ASHE Annual Survey of Hours and Earnings Index

Basis risk The risk resulting from the situation in which the exposure covered by the risk-mitigation technique does not

correspond to the risk exposure of the insurance or reinsurance undertaking"

CAD Canadian Dollars

CEO Chief Executive Officer
CFO Chief Financial Officer

Collateral arrangements

Arrangements under which collateral providers do one of the following: (a) transfer full ownership of the collateral to the collateral taker for the purposes of securing or otherwise covering the performance of a relevant obligation; (b) provide collateral by way of security in favour of, or to, a collateral taker, and the legal ownership of the collateral remains with the collateral provider or a custodian when the security right is

establishedⁱⁱⁱ

Concentration risk All risk exposures with a loss potential which is large enough to threaten the solvency or the financial position

of insurance and reinsurance undertakingsⁱⁱ

Credit risk The risk of loss or of adverse change in the financial situation, resulting from fluctuations in the credit standing

of issuers of securities, counterparties and any debtors to which insurance and reinsurance undertakings are

exposed, in the form of counterparty default risk, or spread risk, or market risk concentrations"

CRO Chief Risk Officer

CSR Corporate and Specialty Risk

Diversification

effects

The reduction in the risk exposure of insurance and reinsurance undertakings and groups related to the diversification of their business, resulting from the fact that the adverse outcome from one risk can be offset by

a more favourable outcome from another risk, where those risks are not fully correlated ii

EIOPA European Insurance and Occupational Pensions Authority

ENID Events Not in Data: These are events not deemed to be captured by the data which need to be separately

allowed for within the best estimate calculations to take appropriate account of uncertainty.

EPIFP Expected profit included in future premium: This is the expected present value of future cash flows which result

from the inclusion in technical provisions of premiums relating to existing insurance and reinsurance contracts that are expected to be received in the future, but that may not be received for any reason, other than because the insured event has occurred, regardless of the legal or contractual rights of the policyholder to discontinue

the policyiii

EUR Euro

FCA Financial Conduct Authority

GAAP Generally accepted accounting principles

GBP Pounds sterling

Gresham Gresham Insurance Company Limited
The Group Aviva plc and its subsidiary companies
IAS International Accounting Standards

IFRS International Financial Reporting Standards (used to prepare the Company's financial statements)

IFRS 13 IFRS covering Fair Value Measurement

IM Internal Model

IMIV Internal Model Independent Validation

IMMMR Identify, measure, manage, monitor and report risks

Latent claims General insurance claims that are often not made until many years after the period of cover provided, due to

the impact of perils or causes not becoming evident for a number of years. Sources of latent claims include

asbestos-related diseases, environmental pollution and industrial deafness.

LIBOR London Interbank Offered Rate

Liquidity risk

The risk that insurance and reinsurance undertakings are unable to realise investments and other assets

in order to settle their financial obligations when they fall due ii

Longevity risk The risk associated with annuitants living longer than expected.

Look through The Company considers the risks, assets, liabilities of its subsidiary as if they were its own.

Market risk The risk of loss or of adverse change in the financial situation resulting, directly or indirectly, from fluctuations

in the level and in the volatility of market prices of assets, liabilities and financial instrumentsⁱⁱ

MCR Minimum Capital Requirement

NED Non-Executive Director

NIC National Indemnity Company

Ocean Marine The Ocean Marine Insurance Company Limited

Operational risk

The risk of loss arising from inadequate or failed internal processes, personnel or systems, or from external

eventsii

ORSA Own Risk and Solvency Assessment

Outsourcing An arrangement of any form between an insurance or reinsurance undertaking and a service provider, whether

a supervised entity or not, by which that service provider performs a process, a service or an activity, whether

directly or by sub-outsourcing, which would otherwise be performed by the insurance or reinsurance

undertaking itself"

Over-the-counter

derivatives

Contracts that are traded (and privately negotiated) directly between two parties, without going through an exchange or other intermediary. Products such as swaps and forward rate agreements are almost always

traded in this way.

PIM Partial Internal Model

PPO Periodic Payment Orders (annuities stemming from non-life insurance contract)

PRA Prudential Regulatory Authority

Probability distribution forecast

A mathematical function that assigns to an exhaustive set of mutually exclusive future events a probability of

realisation"

QRT Quantitative Reporting Templates

Qualifying holding

A direct or indirect holding in an undertaking which represents 10% or more of the capital or of the voting rights or which makes it possible to exercise a significant influence over the management of that undertaking in

Risk Margin An estimate of the amount, in addition to the Best Estimate Liability that a third party would expect to receive

in order to assume ownership of the Company's insurance obligations.

Risk-mitigation techniques

All techniques which enable insurance and reinsurance undertakings to transfer part or all of their risks to

another party"

RPI Retail Prices Index

Scenario analysis The analysis of the impact of a combination of adverse eventsⁱⁱⁱ

SCR Solvency Capital Requirement

SF Standard Formula

SFCR Solvency and Financial Condition Report

SII Solvency II Regulatory Regime

Directive 2009/138/EC of the European Parliament and of the Council on the taking-up and pursuit of the SII Directive

business of Insurance and Reinsurance

Commission delegated regulation (EU) 2015/35 of 10 October 2014 supplementing Directive 2009/138/EC of SII Regulations

the European Parliament and of the Council on the taking-up and pursuit of the business of Insurance and

Reinsurance (Solvency II)

SPV Special Purpose Vehicle: This is any undertaking, whether incorporated or not, other than an existing insurance

or reinsurance undertaking, which assumes risks from insurance or reinsurance undertakings and which fully funds its exposure to such risks through the proceeds of a debt issuance or any other financing mechanism where the repayment rights of the providers of such debt or financing mechanism are subordinated to the

reinsurance obligations of such an undertaking

SST Stress and Scenario Testing

A subordinated loan is a debt which ranks after other debts if a company falls into liquidation or bankruptcy. Subordinated loan

Subrogation is the right for an insurer to legally pursue a third party that caused an insurance loss to the Subrogation

insured. This is done as a means of recovering the amount of the claim paid by the insurance carrier to the

insured for the loss.

UK United Kingdom

USD **US** dollars

Underwriting The risk of loss or of adverse change in the value of insurance liabilities, due to inadequate pricing and

Risk provisioning assumptionsⁱ

The Volatility Adjustment removes temporary distortions in spreads caused by illiquidity in the market or Volatility Adjustment

extreme widening of credit spreads, in particular in relation to government bonds.

i www.aviva.com ii Article 13 SII Directive iii Article 1 SII Regulations

F.3 Directors' Statement

We acknowledge our responsibility for preparing the Solvency and Financial Condition Report of Aviva Insurance Limited at 31 December 2016 in all material respects in accordance with the PRA Rules and the Solvency II Regulations.

The Board is satisfied that to the best of its knowledge and belief:

- (a) throughout the financial year to 31 December 2016, the Company has complied in all material respects with the requirements of the PRA rules and Solvency II Regulations as applicable to the Company; and
- (b) it is reasonable to believe that in respect of the period from 31 December 2016 to the date of the publication of the SFCR, the Company has continued so to comply and that it will continue so to comply for the remainder of the financial year to 31 December 2017.

*CJ Holmes*Director
16 May 2017

Report of the external independent auditors to the Directors of Aviva Insurance Limited ('the Company') pursuant to Rule 4.1 (2) of the External Audit Part of the PRA Rulebook applicable to Solvency II firms

Report on the Audit of the relevant elements of the Solvency and Financial Condition Report

Opinion

Except as stated below, we have audited the following documents prepared by the Company as at 31 December 2016:

- The 'Valuation for solvency purposes' and 'Capital Management' sections of the Solvency and Financial Condition Report of the Company as at 31 December 2016, ('the Narrative Disclosures subject to audit');
 and
- Company templates S.02.01.02, S.12.01.02, S.17.01.02, S.22.01.21, S.23.01.01 and S.28.01.01 ('the Templates subject to audit').

The Narrative Disclosures subject to audit and the Templates subject to audit are collectively referred to as the 'relevant elements of the Solvency and Financial Condition Report'.

We are not required to audit, nor have we audited, and as a consequence do not express an opinion on the **Other Information** which comprises:

- Information contained within the relevant elements of the Solvency and Financial Condition Report set out above which are, or derive from the Solvency Capital Requirement, as identified in the Appendix to this report;
- The 'Summary', 'Business and performance', 'System of governance' and 'Risk profile' elements of the Solvency and Financial Condition Report;
- Company templates S.05.01.02, S.05.02.01, S.19.01.21 and S.25.02.21;
- The written acknowledgement by management of their responsibilities, including for the preparation of the Solvency and Financial Condition Report ('the Responsibility Statement').

To the extent the information subject to audit in the relevant elements of the Solvency and Financial Condition Report includes amounts that are totals, sub-totals or calculations derived from the Other Information, we have relied without verification on the Other Information.

In our opinion, the information subject to audit in the relevant elements of the Solvency and Financial Condition Report of the Company as at 31 December 2016 is prepared, in all material respects, in accordance with the financial reporting provisions of the PRA Rules and Solvency II regulations on which they are based, and as supplemented by supervisory approvals.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) (ISAs (UK & I)), International Standard on Auditing (UK) 800 and International Standard on Auditing (UK) 805, and applicable law. Our responsibilities under those standards are further described in the *Auditors' Responsibilities for the Audit of the relevant elements of the Solvency and Financial Condition Report* section of our report.

Emphasis of Matter - Basis of Accounting

We draw attention to the 'Valuation for solvency purposes' and 'Capital Management' sections of the Solvency and Financial Condition Report, which describe the basis of accounting. The Solvency and Financial Condition Report is prepared in compliance with the financial reporting provisions of the PRA Rules and Solvency II regulations, and therefore in accordance with a special purpose financial reporting framework. The Solvency and Financial Condition Report is required to be published, and intended users include but are not limited to the Prudential Regulation Authority. As a result, the Solvency and Financial Condition Report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

Responsibilities of Directors for the Solvency and Financial Condition Report

The Directors are responsible for the preparation of the Solvency and Financial Condition Report in accordance with the financial reporting provisions of the PRA rules and Solvency II regulations which have been supplemented by the approvals made by the PRA, under the PRA Rules and Solvency II regulations on which they are based, as detailed below:

- Approval to use the volatility adjustment in the calculation of technical provisions.
- Approval to use a partial internal model and the approval of subsequent major changes thereto.

The Directors are also responsible for such internal control as they determine is necessary to enable the preparation of a Solvency and Financial Condition Report that is free from material misstatement, whether due to fraud or error.

Auditors' Responsibilities for the Audit of the relevant elements of the Solvency and Financial Condition Report

It is our responsibility to form an independent opinion, in accordance with applicable law, ISAs (UK & I) and ISAs (UK) 800 and 805 as to whether the information subject to audit in the relevant elements of the Solvency and Financial Condition Report is prepared, in all material respects, in accordance with the financial reporting provisions of the PRA Rules and Solvency II regulations on which they are based. ISAs (UK & I) require us to comply with the Auditing Practices Board's Ethical Standard for Auditors.

An audit involves obtaining evidence about the amounts and disclosures in the relevant elements of the Solvency and Financial Condition Report sufficient to give reasonable assurance that the relevant elements of the Solvency and Financial Condition Report are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the Company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the Directors; and the overall presentation of the relevant elements of the Solvency and Financial Condition Report. In addition, we read all the financial and non-financial information in the Solvency and Financial Condition Report to identify material inconsistencies with the audited relevant elements of the Solvency and Financial Condition Report. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

This report, including the opinion, has been prepared for the Directors of the Company to comply with their obligations under External Audit rule 2.1 of the Solvency II firms Sector of the PRA Rulebook and for no other purpose. We do not, in providing this report, accept or assume responsibility for any other purpose save where expressly agreed by our prior consent in writing.

Other Matter

The Company has authority to calculate its Solvency Capital Requirement using a partial internal model ('the Model') approved by the Prudential Regulation Authority in accordance with the Solvency II Regulations. In forming our opinion (and in accordance with PRA Rules), we are not required to audit the inputs to, design of, operating effectiveness of and outputs from the Model, or whether the Model is being applied in accordance with the Company's application or approval order.

Report on Other Legal and Regulatory Requirements

In accordance with Rule 4.1 (3) of the External Audit Part of the PRA Rulebook for Solvency II firms we are required to read the Other Information and consider whether it is materially inconsistent with the relevant elements of the Solvency and Financial Condition Report and our knowledge obtained in the audits of the Solvency and Financial Condition Report and of the Company's statutory financial statements. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

PricewaterhouseCoopers LLP Chartered Accountants London 16 May 2017

- The maintenance and integrity of the Aviva plc website is the responsibility of the directors; the work carried out by the auditors does not involve consideration of these matters and, accordingly, the auditors accept no responsibility for any changes that may have occurred to the Solvency and Financial Condition Report since it was initially presented on the website.
- Legislation in the United Kingdom governing the preparation and dissemination of Solvency and Financial Condition Reports may differ from legislation in other jurisdictions.

Appendix - relevant elements of the Solvency and Financial Condition Report that are not subject to audit

The relevant elements of the Solvency and Financial Condition Report that are not subject to audit comprise:

- The following elements of template S.02.01.02:
 - Row R0550: Technical provisions non-life (excluding health) risk margin
 - Row R0590: Technical provisions health (similar to non-life) risk margin
 - Row R0640: Technical provisions health (similar to life) risk margin
 - Row R0680: Technical provisions life (excluding health and index-linked and unit-linked) risk margin
 - Row R0720: Technical provisions Index-linked and unit-linked risk margin
- The following elements of template S.12.01.02
 - Row R0100: Technical provisions calculated as a sum of BE and RM Risk margin
- The following elements of template S.17.01.02
 - Row R0280: Technical provisions calculated as a sum of BE and RM Risk margin
- The following elements of template S.22.01.21
 - Row R0010 Technical provisions
 - Row R0090 Solvency Capital Requirement
- The following elements of template S.23.01.01
 - Row R0580: SCR
 - Row R0740: Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds
- The following elements of Company template S.28.01.01
 - Row R0310: SCR
- Elements of the Narrative Disclosures subject to audit identified as 'unaudited'.